JP5475672B2 - c−fmsキナーゼの阻害剤 - Google Patents
c−fmsキナーゼの阻害剤 Download PDFInfo
- Publication number
- JP5475672B2 JP5475672B2 JP2010530095A JP2010530095A JP5475672B2 JP 5475672 B2 JP5475672 B2 JP 5475672B2 JP 2010530095 A JP2010530095 A JP 2010530095A JP 2010530095 A JP2010530095 A JP 2010530095A JP 5475672 B2 JP5475672 B2 JP 5475672B2
- Authority
- JP
- Japan
- Prior art keywords
- dimethyl
- compound
- enyl
- alkyl
- cyclohex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 title description 12
- 239000003112 inhibitor Substances 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims description 287
- -1 4,4-dimethyl-cyclohex-1-enyl Chemical group 0.000 claims description 201
- 239000000203 mixture Substances 0.000 claims description 87
- XTDRPNJABDWQFI-UHFFFAOYSA-N 5-cyano-1h-imidazole-2-carboxylic acid Chemical compound OC(=O)C1=NC(C#N)=CN1 XTDRPNJABDWQFI-UHFFFAOYSA-N 0.000 claims description 69
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 238000011282 treatment Methods 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000012453 solvate Substances 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 241000124008 Mammalia Species 0.000 claims description 25
- 206010003246 arthritis Diseases 0.000 claims description 20
- 206010027476 Metastases Diseases 0.000 claims description 19
- 230000009401 metastasis Effects 0.000 claims description 19
- 229920006395 saturated elastomer Polymers 0.000 claims description 19
- 239000000460 chlorine Substances 0.000 claims description 18
- 230000002757 inflammatory effect Effects 0.000 claims description 16
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 15
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims description 14
- 201000008482 osteoarthritis Diseases 0.000 claims description 14
- 206010009944 Colon cancer Diseases 0.000 claims description 13
- 206010060862 Prostate cancer Diseases 0.000 claims description 13
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 13
- 201000004681 Psoriasis Diseases 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 206010033128 Ovarian cancer Diseases 0.000 claims description 12
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 12
- 150000004677 hydrates Chemical class 0.000 claims description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 208000020816 lung neoplasm Diseases 0.000 claims description 11
- 206010046766 uterine cancer Diseases 0.000 claims description 11
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 10
- 206010017758 gastric cancer Diseases 0.000 claims description 10
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 10
- 201000011549 stomach cancer Diseases 0.000 claims description 10
- 230000033115 angiogenesis Effects 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 206010016654 Fibrosis Diseases 0.000 claims description 8
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 8
- 208000001132 Osteoporosis Diseases 0.000 claims description 8
- 208000027868 Paget disease Diseases 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 210000000988 bone and bone Anatomy 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 230000004761 fibrosis Effects 0.000 claims description 8
- 208000027202 mammary Paget disease Diseases 0.000 claims description 8
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 8
- 230000000010 osteolytic effect Effects 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 208000037803 restenosis Diseases 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 206010006002 Bone pain Diseases 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 206010065390 Inflammatory pain Diseases 0.000 claims description 6
- 208000011623 Obstructive Lung disease Diseases 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 206010033645 Pancreatitis Diseases 0.000 claims description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 6
- 206010046851 Uveitis Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 201000000306 sarcoidosis Diseases 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 208000009935 visceral pain Diseases 0.000 claims description 6
- 125000000392 cycloalkenyl group Chemical class 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000001544 thienyl group Chemical class 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims description 3
- SURSLNROICJHHG-FHIDHQGESA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1h-imidazole-2-carboxamide;[(4s)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C.C1C(C)(C)CCC(C=2C(=CC=C(N=2)C2CC(C)(C)OC(C)(C)C2)NC(=O)C=2NC(=CN=2)C#N)=C1 SURSLNROICJHHG-FHIDHQGESA-N 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 132
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 129
- 238000000034 method Methods 0.000 description 99
- 238000001819 mass spectrum Methods 0.000 description 86
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 66
- 235000019439 ethyl acetate Nutrition 0.000 description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 56
- 239000000243 solution Substances 0.000 description 56
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 54
- 239000007787 solid Substances 0.000 description 45
- 239000011734 sodium Substances 0.000 description 43
- 238000005160 1H NMR spectroscopy Methods 0.000 description 42
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 42
- 230000002829 reductive effect Effects 0.000 description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 36
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 34
- 239000002904 solvent Substances 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- SQMINWFWFXVWHK-UHFFFAOYSA-N 4-cyano-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxylic acid Chemical compound C[Si](C)(C)CCOCN1C=C(C#N)N=C1C(O)=O SQMINWFWFXVWHK-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 24
- 239000003921 oil Substances 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 22
- 229910002027 silica gel Inorganic materials 0.000 description 22
- 229910052786 argon Inorganic materials 0.000 description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 19
- 239000012044 organic layer Substances 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 125000006239 protecting group Chemical group 0.000 description 18
- 238000010898 silica gel chromatography Methods 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 16
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 16
- 239000002253 acid Substances 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 14
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 13
- 239000011701 zinc Substances 0.000 description 13
- 0 CC1=N*C(N)=N1 Chemical compound CC1=N*C(N)=N1 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 12
- 238000000634 powder X-ray diffraction Methods 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- 150000001768 cations Chemical class 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- WUEVEAZIMNIMQX-UHFFFAOYSA-N n-[4-bromo-2-(4,4-dimethylcyclohexen-1-yl)phenyl]-5-cyano-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(Br)C=2)NC(=O)C=2NC=C(N=2)C#N)=C1 WUEVEAZIMNIMQX-UHFFFAOYSA-N 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 125000004093 cyano group Chemical group *C#N 0.000 description 9
- 229910052763 palladium Inorganic materials 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 229940126062 Compound A Drugs 0.000 description 8
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 7
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229910052744 lithium Inorganic materials 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- BNVPFDRNGHMRJS-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(N=2)C2CC(C)(C)OC(C)(C)C2)NC(=O)C=2NC=C(N=2)C#N)=C1 BNVPFDRNGHMRJS-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000003423 ankle Anatomy 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 125000002883 imidazolyl group Chemical group 0.000 description 6
- 150000002576 ketones Chemical class 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000000527 sonication Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000002411 thermogravimetry Methods 0.000 description 6
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- HWFBGGLUEZIDOE-UHFFFAOYSA-N (4,4-dimethylcyclohexen-1-yl)boronic acid Chemical compound CC1(C)CCC(B(O)O)=CC1 HWFBGGLUEZIDOE-UHFFFAOYSA-N 0.000 description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 5
- 150000001336 alkenes Chemical class 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 238000005695 dehalogenation reaction Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- SAMNBOHOBWEEEU-UHFFFAOYSA-N tetrabromoacetone Natural products BrC(Br)C(=O)C(Br)Br SAMNBOHOBWEEEU-UHFFFAOYSA-N 0.000 description 5
- UQCWXKSHRQJGPH-UHFFFAOYSA-M tetrabutylazanium;fluoride;hydrate Chemical compound O.[F-].CCCC[N+](CCCC)(CCCC)CCCC UQCWXKSHRQJGPH-UHFFFAOYSA-M 0.000 description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 229960001456 adenosine triphosphate Drugs 0.000 description 4
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 238000006114 decarboxylation reaction Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000002875 fluorescence polarization Methods 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- BNQGKHUEVQWESM-UHFFFAOYSA-M potassium;4-cyano-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxylate Chemical compound [K+].C[Si](C)(C)CCOCN1C=C(C#N)N=C1C([O-])=O BNQGKHUEVQWESM-UHFFFAOYSA-M 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 159000000000 sodium salts Chemical group 0.000 description 4
- 150000003457 sulfones Chemical class 0.000 description 4
- 150000003462 sulfoxides Chemical class 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002096 two-dimensional nuclear Overhauser enhancement spectroscopy Methods 0.000 description 4
- DXLQEJHUQKKSRB-UHFFFAOYSA-N 1,1,1-trifluoro-n-pyridin-2-yl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=N1 DXLQEJHUQKKSRB-UHFFFAOYSA-N 0.000 description 3
- LIEGFHGAQAVFGV-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4-nonafluoro-butane-1-sulfonic acid1,4,4,7-tetramethyl-3,5,11-trioxa-tricyclo[5.3.1.02,6]undec-8-en-9-yl ester Chemical compound O1C2(C)C3OC(C)(C)OC3C1(C)C=C(OS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C2 LIEGFHGAQAVFGV-UHFFFAOYSA-N 0.000 description 3
- DZEPFNDOOWFEKN-UHFFFAOYSA-N 2,5-bis(methoxymethyl)furan Chemical compound COCC1=CC=C(COC)O1 DZEPFNDOOWFEKN-UHFFFAOYSA-N 0.000 description 3
- ITTGPGCIKBBGDY-UHFFFAOYSA-N 2-bromo-4-(2,2,6,6-tetramethyl-1,1-dioxothian-4-yl)aniline Chemical compound C1C(C)(C)S(=O)(=O)C(C)(C)CC1C1=CC=C(N)C(Br)=C1 ITTGPGCIKBBGDY-UHFFFAOYSA-N 0.000 description 3
- HUUFTVUBFFESEN-UHFFFAOYSA-N 2-bromo-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Br)N=C1 HUUFTVUBFFESEN-UHFFFAOYSA-N 0.000 description 3
- QMJRZYBRTXNTCC-UHFFFAOYSA-N 2-bromo-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-amine Chemical compound C1C(C)(C)OC(C)(C)CC1C1=CC=C(N)C(Br)=N1 QMJRZYBRTXNTCC-UHFFFAOYSA-N 0.000 description 3
- FPRWZXKKPQVCQP-UHFFFAOYSA-N 4-(2,2,6,6-tetramethyl-3h-thiopyran-4-yl)aniline Chemical compound CC1(C)SC(C)(C)CC(C=2C=CC(N)=CC=2)=C1 FPRWZXKKPQVCQP-UHFFFAOYSA-N 0.000 description 3
- OQHKEVATSGWALO-UHFFFAOYSA-N 4-bromo-2-(4,4-dimethylcyclohexen-1-yl)aniline Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(Br)C=2)N)=C1 OQHKEVATSGWALO-UHFFFAOYSA-N 0.000 description 3
- GDFIUUZLRLJTSJ-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1h-imidazole-2-carboxamide;hydrochloride Chemical compound Cl.C1C(C)(C)CCC(C=2C(=CC=C(N=2)C2CC(C)(C)OC(C)(C)C2)NC(=O)C=2NC=C(N=2)C#N)=C1 GDFIUUZLRLJTSJ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 241000872931 Myoporum sandwicense Species 0.000 description 3
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
- GLCJANLAKISVBJ-PKTZIBPZSA-N PG-PS Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCC(O)=O GLCJANLAKISVBJ-PKTZIBPZSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 238000007110 [4+3]-cycloaddition reaction Methods 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000007819 coupling partner Substances 0.000 description 3
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 3
- 150000001993 dienes Chemical class 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 238000010931 ester hydrolysis Methods 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000012038 nucleophile Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- LUYQYZLEHLTPBH-UHFFFAOYSA-N perfluorobutanesulfonyl fluoride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(F)(=O)=O LUYQYZLEHLTPBH-UHFFFAOYSA-N 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- CFGZSXWIAPHZMD-UHFFFAOYSA-N 1,4,4,7-tetramethyl-3,5,11-trioxa-tricyclo[5.3.1.02,6]undecan-9-one Chemical compound C1C(=O)CC2(C)C3OC(C)(C)OC3C1(C)O2 CFGZSXWIAPHZMD-UHFFFAOYSA-N 0.000 description 2
- YHDKWPUAGMYSCL-UHFFFAOYSA-N 1,4,4,7-tetramethyl-9-(4-nitrophenyl)-3,5,11-trioxatricyclo[5.3.1.02,6]undec-8-ene Chemical compound O1C(C)(C)OC2C1C(C=1)(C)OC2(C)CC=1C1=CC=C([N+]([O-])=O)C=C1 YHDKWPUAGMYSCL-UHFFFAOYSA-N 0.000 description 2
- UINBUHBGQCQOCX-UHFFFAOYSA-N 1,5-bis(2-tert-butylsilyloxypropan-2-yl)-8-oxabicyclo[3.2.1]oct-6-en-3-one Chemical compound C1C(=O)CC2(C(C)(C)O[SiH2]C(C)(C)C)C=CC1(C(C)(C)O[SiH2]C(C)(C)C)O2 UINBUHBGQCQOCX-UHFFFAOYSA-N 0.000 description 2
- PBCUWMUVHALVHC-UHFFFAOYSA-N 1,5-bis(2-tert-butylsilyloxypropan-2-yl)-8-oxabicyclo[3.2.1]octan-3-one Chemical compound C1C(=O)CC2(C(C)(C)O[SiH2]C(C)(C)C)CCC1(C(C)(C)O[SiH2]C(C)(C)C)O2 PBCUWMUVHALVHC-UHFFFAOYSA-N 0.000 description 2
- QCVVEELKXRXRJF-UHFFFAOYSA-N 1,5-bis(methoxymethyl)-8-oxabicyclo[3.2.1]oct-6-en-3-one Chemical compound C1C(=O)CC2(COC)C=CC1(COC)O2 QCVVEELKXRXRJF-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- KYWMCFOWDYFYLV-UHFFFAOYSA-N 1h-imidazole-2-carboxylic acid Chemical compound OC(=O)C1=NC=CN1 KYWMCFOWDYFYLV-UHFFFAOYSA-N 0.000 description 2
- GJVXQIBOHYDHNS-UHFFFAOYSA-N 2,2,6,6-tetramethyl-4-(5-nitropyridin-2-yl)-3h-thiopyran 1,1-dioxide Chemical compound CC1(C)S(=O)(=O)C(C)(C)CC(C=2N=CC(=CC=2)[N+]([O-])=O)=C1 GJVXQIBOHYDHNS-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- JQEUELMRQYUNDS-UHFFFAOYSA-N 2-(4,4-dimethylcyclohexen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCC(C)(C)CC1 JQEUELMRQYUNDS-UHFFFAOYSA-N 0.000 description 2
- CXGCJUZHDGWXGL-UHFFFAOYSA-N 2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyl-1,1-dioxothian-4-yl)pyridin-3-amine Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(N=2)C2CC(C)(C)S(=O)(=O)C(C)(C)C2)N)=C1 CXGCJUZHDGWXGL-UHFFFAOYSA-N 0.000 description 2
- CMOSFDXYSWTZNG-UHFFFAOYSA-N 2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-amine Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(N=2)C2CC(C)(C)OC(C)(C)C2)N)=C1 CMOSFDXYSWTZNG-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- WAWZRGOXTNWJAN-UHFFFAOYSA-N 2-bromo-6-(2,2,6,6-tetramethyl-1,1-dioxothian-4-yl)pyridin-3-amine Chemical compound C1C(C)(C)S(=O)(=O)C(C)(C)CC1C1=CC=C(N)C(Br)=N1 WAWZRGOXTNWJAN-UHFFFAOYSA-N 0.000 description 2
- VOXXPMAJNSVUKJ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-(2,2,6,6-tetramethyl-3h-pyran-4-yl)-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC(C)(C)OC(C)(C)C1 VOXXPMAJNSVUKJ-UHFFFAOYSA-N 0.000 description 2
- BDGKOSBTEWNBMO-UHFFFAOYSA-N 4-(2,2,6,6-tetramethyl-1,1-dioxo-3h-thiopyran-4-yl)aniline Chemical compound CC1(C)S(=O)(=O)C(C)(C)CC(C=2C=CC(N)=CC=2)=C1 BDGKOSBTEWNBMO-UHFFFAOYSA-N 0.000 description 2
- OAIVVYTWBSMFLO-UHFFFAOYSA-N 4-(2,2,6,6-tetramethyl-1,1-dioxothian-4-yl)aniline Chemical compound C1C(C)(C)S(=O)(=O)C(C)(C)CC1C1=CC=C(N)C=C1 OAIVVYTWBSMFLO-UHFFFAOYSA-N 0.000 description 2
- ZANPJXNYBVVNSD-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N)C=C1 ZANPJXNYBVVNSD-UHFFFAOYSA-N 0.000 description 2
- NZTXLIMZFJQITA-UHFFFAOYSA-N 4-[1,5-bis(2-tert-butylsilyloxypropan-2-yl)-8-oxabicyclo[3.2.1]octa-2,6-dien-3-yl]aniline Chemical compound C=1C(C(C)(C)O[SiH2]C(C)(C)C)(C=C2)OC2(C(C)(C)O[SiH2]C(C)(C)C)CC=1C1=CC=C(N)C=C1 NZTXLIMZFJQITA-UHFFFAOYSA-N 0.000 description 2
- KKGYLTUUVKWUJT-UHFFFAOYSA-N 4-[1,5-bis(methoxymethyl)-8-oxabicyclo[3.2.1]octa-3,6-dien-3-yl]aniline Chemical compound C=1C(COC)(C=C2)OC2(COC)CC=1C1=CC=C(N)C=C1 KKGYLTUUVKWUJT-UHFFFAOYSA-N 0.000 description 2
- HTRVQBOXCCYIPW-UHFFFAOYSA-N 4-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-4-(2,2,6,6-tetramethyl-1,1-dioxothian-4-yl)phenyl]-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(C=2)C2CC(C)(C)S(=O)(=O)C(C)(C)C2)NC(=O)C=2N(C=C(N=2)C#N)COCC[Si](C)(C)C)=C1 HTRVQBOXCCYIPW-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- MKUNMRWXBFKQBO-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-4-(8-oxabicyclo[3.2.1]octa-3,6-dien-3-yl)phenyl]-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(C=2)C=2CC3OC(C=C3)C=2)NC(=O)C=2NC=C(N=2)C#N)=C1 MKUNMRWXBFKQBO-UHFFFAOYSA-N 0.000 description 2
- ITGMISQHAOCOCS-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1h-imidazole-2-carboxamide;sodium Chemical compound [Na].C1C(C)(C)CCC(C=2C(=CC=C(N=2)C2CC(C)(C)OC(C)(C)C2)NC(=O)C=2NC(=CN=2)C#N)=C1 ITGMISQHAOCOCS-UHFFFAOYSA-N 0.000 description 2
- CGDXRKPVKUETNT-UHFFFAOYSA-N 5-nitro-2-(2,2,6,6-tetramethyl-3h-pyran-4-yl)pyridine Chemical compound CC1(C)OC(C)(C)CC(C=2N=CC(=CC=2)[N+]([O-])=O)=C1 CGDXRKPVKUETNT-UHFFFAOYSA-N 0.000 description 2
- NWIYSAJIMBOMOG-UHFFFAOYSA-N 5-nitro-2-(2,2,6,6-tetramethyl-3h-thiopyran-4-yl)pyridine Chemical compound CC1(C)SC(C)(C)CC(C=2N=CC(=CC=2)[N+]([O-])=O)=C1 NWIYSAJIMBOMOG-UHFFFAOYSA-N 0.000 description 2
- UAQDBDBZCSTERP-UHFFFAOYSA-N 6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-amine Chemical compound C1C(C)(C)OC(C)(C)CC1C1=CC=C(N)C=N1 UAQDBDBZCSTERP-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical class C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- SQTFRSAJTTYYOF-UHFFFAOYSA-N [1,5-bis(2-tert-butylsilyloxypropan-2-yl)-8-oxabicyclo[3.2.1]octa-2,6-dien-3-yl] trifluoromethanesulfonate Chemical compound C1C(OS(=O)(=O)C(F)(F)F)=CC2(C(C)(C)O[SiH2]C(C)(C)C)C=CC1(C(C)(C)O[SiH2]C(C)(C)C)O2 SQTFRSAJTTYYOF-UHFFFAOYSA-N 0.000 description 2
- UJDLUELYYBKNRP-UHFFFAOYSA-N [1,5-bis(methoxymethyl)-8-oxabicyclo[3.2.1]octa-3,6-dien-3-yl] trifluoromethanesulfonate Chemical compound C1C(OS(=O)(=O)C(F)(F)F)=CC2(COC)C=CC1(COC)O2 UJDLUELYYBKNRP-UHFFFAOYSA-N 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 125000005620 boronic acid group Chemical class 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000002967 competitive immunoassay Methods 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- XZWQKJXJNKYMAP-UHFFFAOYSA-N cyclohexen-1-ylboronic acid Chemical compound OB(O)C1=CCCCC1 XZWQKJXJNKYMAP-UHFFFAOYSA-N 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 150000002085 enols Chemical class 0.000 description 2
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical group Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002768 hair cell Anatomy 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 238000011694 lewis rat Methods 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910000000 metal hydroxide Inorganic materials 0.000 description 2
- 150000004692 metal hydroxides Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- GIHROXKYXZOBHI-UHFFFAOYSA-N n'-[4-bromo-2-(4,4-dimethylcyclohexen-1-yl)phenyl]-n,n-dimethylmethanimidamide Chemical compound CN(C)C=NC1=CC=C(Br)C=C1C1=CCC(C)(C)CC1 GIHROXKYXZOBHI-UHFFFAOYSA-N 0.000 description 2
- BXGTVNLGPMZLAZ-UHFFFAOYSA-N n'-ethylmethanediimine;hydrochloride Chemical compound Cl.CCN=C=N BXGTVNLGPMZLAZ-UHFFFAOYSA-N 0.000 description 2
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 2
- RRBIIRATEAFMIL-UHFFFAOYSA-N n-[4-bromo-2-(4,4-dimethylcyclohexen-1-yl)phenyl]-4-cyano-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(Br)C=2)NC(=O)C=2N(C=C(N=2)C#N)COCC[Si](C)(C)C)=C1 RRBIIRATEAFMIL-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000001979 organolithium group Chemical group 0.000 description 2
- 125000002734 organomagnesium group Chemical group 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- JGTNAGYHADQMCM-UHFFFAOYSA-N perfluorobutanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F JGTNAGYHADQMCM-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 150000003852 triazoles Chemical group 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- BWMAJEKSEBIOPI-UHFFFAOYSA-N (2,2,6,6-tetramethyl-3h-thiopyran-4-yl) 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate Chemical compound CC1(C)CC(OS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)=CC(C)(C)S1 BWMAJEKSEBIOPI-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WIKBZUXHNPONPP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoro-2-iodo-2-(trifluoromethyl)propane Chemical compound FC(F)(F)C(I)(C(F)(F)F)C(F)(F)F WIKBZUXHNPONPP-UHFFFAOYSA-N 0.000 description 1
- RVSIFWBAGVMQKT-UHFFFAOYSA-N 1,1,1,3,3-pentachloropropan-2-one Chemical compound ClC(Cl)C(=O)C(Cl)(Cl)Cl RVSIFWBAGVMQKT-UHFFFAOYSA-N 0.000 description 1
- WQZLUKNOWXXMFL-UHFFFAOYSA-N 1,1,1,3-tetrabromopropan-2-one Chemical compound BrCC(=O)C(Br)(Br)Br WQZLUKNOWXXMFL-UHFFFAOYSA-N 0.000 description 1
- SMZHKGXSEAGRTI-UHFFFAOYSA-N 1,1,1-trichloropropan-2-one Chemical compound CC(=O)C(Cl)(Cl)Cl SMZHKGXSEAGRTI-UHFFFAOYSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- UOIYFFUKPHIOFF-UHFFFAOYSA-N 1,5-dimethyl-8-oxabicyclo[3.2.1]oct-6-en-3-one Chemical compound C1C(=O)CC2(C)C=CC1(C)O2 UOIYFFUKPHIOFF-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- QMQZIXCNLUPEIN-UHFFFAOYSA-N 1h-imidazole-2-carbonitrile Chemical compound N#CC1=NC=CN1 QMQZIXCNLUPEIN-UHFFFAOYSA-N 0.000 description 1
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 description 1
- CGAPIUWHWGPGJN-UHFFFAOYSA-N 2,2,6,6-tetramethylthian-4-one Chemical compound CC1(C)CC(=O)CC(C)(C)S1 CGAPIUWHWGPGJN-UHFFFAOYSA-N 0.000 description 1
- DSLRVRBSNLHVBH-UHFFFAOYSA-N 2,5-furandimethanol Chemical compound OCC1=CC=C(CO)O1 DSLRVRBSNLHVBH-UHFFFAOYSA-N 0.000 description 1
- NSYGEZDLAUTAPK-UHFFFAOYSA-N 2-(4,4-dimethylcyclohexen-1-yl)-4-(2,2,6,6-tetramethyl-1,1-dioxothian-4-yl)aniline Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(C=2)C2CC(C)(C)S(=O)(=O)C(C)(C)C2)N)=C1 NSYGEZDLAUTAPK-UHFFFAOYSA-N 0.000 description 1
- NDZWFQHHEJEMJU-UHFFFAOYSA-N 2-(4,4-dimethylcyclohexen-1-yl)aniline Chemical compound C1C(C)(C)CCC(C=2C(=CC=CC=2)N)=C1 NDZWFQHHEJEMJU-UHFFFAOYSA-N 0.000 description 1
- WFXYSIUKXBDIRJ-UHFFFAOYSA-N 2-(cyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-amine Chemical compound C1C(C)(C)OC(C)(C)CC1C1=CC=C(N)C(C=2CCCCC=2)=N1 WFXYSIUKXBDIRJ-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- AOPBDRUWRLBSDB-UHFFFAOYSA-N 2-bromoaniline Chemical compound NC1=CC=CC=C1Br AOPBDRUWRLBSDB-UHFFFAOYSA-N 0.000 description 1
- AAEZMHSWRQVQEK-UHFFFAOYSA-N 2-methylideneoxirane Chemical compound C=C1CO1 AAEZMHSWRQVQEK-UHFFFAOYSA-N 0.000 description 1
- SVOCLWUDDWXHFW-UHFFFAOYSA-N 2-methylsulfanyl-1h-imidazole Chemical compound CSC1=NC=CN1 SVOCLWUDDWXHFW-UHFFFAOYSA-N 0.000 description 1
- JITRGYCOZQHMIE-UHFFFAOYSA-N 4,4-di-tert-butyl-1,7-dimethyl-3,5,11-trioxa-4-sila-tricyclo[5.3.1.02,6]undecan-9-one Chemical compound C1C(=O)CC2(C)C3O[Si](C(C)(C)C)(C(C)(C)C)OC3C1(C)O2 JITRGYCOZQHMIE-UHFFFAOYSA-N 0.000 description 1
- QUTLCVZXLLGTNP-UHFFFAOYSA-N 4-[1,5-bis(2-tert-butylsilyloxypropan-2-yl)-8-oxabicyclo[3.2.1]oct-2-en-3-yl]aniline Chemical compound O1C(C(C)(C)O[SiH2]C(C)(C)C)(C2)CCC1(C(C)(C)O[SiH2]C(C)(C)C)C=C2C1=CC=C(N)C=C1 QUTLCVZXLLGTNP-UHFFFAOYSA-N 0.000 description 1
- HHTYEQWCHQEJNV-UHFFFAOYSA-N 4-bromo-2-iodoaniline Chemical compound NC1=CC=C(Br)C=C1I HHTYEQWCHQEJNV-UHFFFAOYSA-N 0.000 description 1
- KSESVRGMJUKHAN-UHFFFAOYSA-N 4-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(N=2)C2CC(C)(C)OC(C)(C)C2)NC(=O)C=2N(C=C(N=2)C#N)COCC[Si](C)(C)C)=C1 KSESVRGMJUKHAN-UHFFFAOYSA-N 0.000 description 1
- VWHPPZCUSCVKKZ-UHFFFAOYSA-N 4-cyano-n-[2-(cyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxamide Chemical compound C1C(C)(C)OC(C)(C)CC1C(N=C1C=2CCCCC=2)=CC=C1NC(=O)C1=NC(C#N)=CN1COCC[Si](C)(C)C VWHPPZCUSCVKKZ-UHFFFAOYSA-N 0.000 description 1
- IJHJSHFKVNEYSN-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-4-(2,2,6,6-tetramethyl-1,1-dioxothian-4-yl)phenyl]-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(C=2)C2CC(C)(C)S(=O)(=O)C(C)(C)C2)NC(=O)C=2NC=C(N=2)C#N)=C1 IJHJSHFKVNEYSN-UHFFFAOYSA-N 0.000 description 1
- XAHCYEBHJYPIDD-UHFFFAOYSA-N 5-cyano-n-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyl-1,1-dioxothian-4-yl)pyridin-3-yl]-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(N=2)C2CC(C)(C)S(=O)(=O)C(C)(C)C2)NC(=O)C=2NC=C(N=2)C#N)=C1 XAHCYEBHJYPIDD-UHFFFAOYSA-N 0.000 description 1
- UQFCFPLMDJGELA-UHFFFAOYSA-N 5-ethyl-1h-imidazole-2-carboxylic acid Chemical compound CCC1=CN=C(C(O)=O)N1 UQFCFPLMDJGELA-UHFFFAOYSA-N 0.000 description 1
- KHCQMRLNERQHKR-UHFFFAOYSA-N 6,7-dihydroxy-1,5-dimethyl-8-oxabicyclo[3.2.1]octan-3-one Chemical compound C1C(=O)CC2(C)C(O)C(O)C1(C)O2 KHCQMRLNERQHKR-UHFFFAOYSA-N 0.000 description 1
- PLUVDWVRHICEAD-UHFFFAOYSA-N 6-(2,2,6,6-tetramethyl-1,1-dioxothian-4-yl)pyridin-3-amine Chemical compound C1C(C)(C)S(=O)(=O)C(C)(C)CC1C1=CC=C(N)C=N1 PLUVDWVRHICEAD-UHFFFAOYSA-N 0.000 description 1
- DJXYBPVHUSVRLJ-UHFFFAOYSA-N 8-oxabicyclo[3.2.1]oct-6-en-3-one Chemical compound C1C(=O)CC2C=CC1O2 DJXYBPVHUSVRLJ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- WVLZYYISYCJJMH-IPHFVPNQSA-N CC(C)(CC1)CC=C1c(nc(C(CC1(C)C)CC(C)(C)S1(=O)=O)cc1)c1NC(c1nc(/C=N\C)c[n]1COCC[Si+](C)(C)C)=O Chemical compound CC(C)(CC1)CC=C1c(nc(C(CC1(C)C)CC(C)(C)S1(=O)=O)cc1)c1NC(c1nc(/C=N\C)c[n]1COCC[Si+](C)(C)C)=O WVLZYYISYCJJMH-IPHFVPNQSA-N 0.000 description 1
- DRWIHBMYXOLPTO-UHFFFAOYSA-N CC1(CC=CC(S1(=O)=O)(C)C)C Chemical compound CC1(CC=CC(S1(=O)=O)(C)C)C DRWIHBMYXOLPTO-UHFFFAOYSA-N 0.000 description 1
- YNUXXWLCFLJELN-UHFFFAOYSA-N CC12CC(CC(O1)(C3(C2O[SiH2]O3)C(C)(C)C)C)O Chemical compound CC12CC(CC(O1)(C3(C2O[SiH2]O3)C(C)(C)C)C)O YNUXXWLCFLJELN-UHFFFAOYSA-N 0.000 description 1
- BBEXBXMKOCJPQM-UHFFFAOYSA-N CC1=C(C2CC(=O)CC1N2C(=O)OC)C Chemical compound CC1=C(C2CC(=O)CC1N2C(=O)OC)C BBEXBXMKOCJPQM-UHFFFAOYSA-N 0.000 description 1
- CBDMDWXBABLTEK-UHFFFAOYSA-N CCN(CC)CC.OCC(F)(F)F Chemical compound CCN(CC)CC.OCC(F)(F)F CBDMDWXBABLTEK-UHFFFAOYSA-N 0.000 description 1
- PWLFJYHNWYQQMF-FUHWJXTLSA-N COCCCC[C@](COC)(C1)OCC[C@@H]1c(cc1)ccc1N Chemical compound COCCCC[C@](COC)(C1)OCC[C@@H]1c(cc1)ccc1N PWLFJYHNWYQQMF-FUHWJXTLSA-N 0.000 description 1
- PWLFJYHNWYQQMF-SJLPKXTDSA-N COCCCC[C@](COC)(C1)OCC[C@H]1c(cc1)ccc1N Chemical compound COCCCC[C@](COC)(C1)OCC[C@H]1c(cc1)ccc1N PWLFJYHNWYQQMF-SJLPKXTDSA-N 0.000 description 1
- GTUWRDQVIYPJEZ-WOOKNIGNSA-N C[C@H](C1OC(C2)C=CC1)[C@@]2(C)OI Chemical compound C[C@H](C1OC(C2)C=CC1)[C@@]2(C)OI GTUWRDQVIYPJEZ-WOOKNIGNSA-N 0.000 description 1
- QYBJWNQEXWMVNH-ILWJIGKKSA-N C[C@]1(C[C@](C)(C2)O)O[C@]2(C)C=C1 Chemical compound C[C@]1(C[C@](C)(C2)O)O[C@]2(C)C=C1 QYBJWNQEXWMVNH-ILWJIGKKSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 238000007355 Double Michael addition reaction Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101000916629 Mus musculus Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 1
- 101710084411 POU domain, class 2, transcription factor 2 Proteins 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 238000003482 Pinner synthesis reaction Methods 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- LCKIEQZJEYYRIY-UHFFFAOYSA-N Titanium ion Chemical compound [Ti+4] LCKIEQZJEYYRIY-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052977 alkali metal sulfide Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- LPCWKMYWISGVSK-UHFFFAOYSA-N bicyclo[3.2.1]octane Chemical compound C1C2CCC1CCC2 LPCWKMYWISGVSK-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- VBBRYJMZLIYUJQ-UHFFFAOYSA-N cyclopropanone Chemical compound O=C1CC1 VBBRYJMZLIYUJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- PDYPRPVKBUOHDH-UHFFFAOYSA-N ditert-butyl(dichloro)silane Chemical compound CC(C)(C)[Si](Cl)(Cl)C(C)(C)C PDYPRPVKBUOHDH-UHFFFAOYSA-N 0.000 description 1
- JTGAUXSVQKWNHO-UHFFFAOYSA-N ditert-butylsilicon Chemical group CC(C)(C)[Si]C(C)(C)C JTGAUXSVQKWNHO-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- MSMGXWFHBSCQFB-UHFFFAOYSA-N ethyl cyanoformate Chemical compound CCOC(=O)C#N MSMGXWFHBSCQFB-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000007172 homogeneous catalysis Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052976 metal sulfide Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- WCHNKWDOYKWYPN-UHFFFAOYSA-N methyl 1,5-dimethyl-3-oxo-8-azabicyclo[3.2.1]oct-6-ene-8-carboxylate Chemical compound C1C(=O)CC2(C)C=CC1(C)N2C(=O)OC WCHNKWDOYKWYPN-UHFFFAOYSA-N 0.000 description 1
- YRTOCIAZPCWZPU-UHFFFAOYSA-N methyl 2,5-dimethylpyrrole-1-carboxylate Chemical compound COC(=O)N1C(C)=CC=C1C YRTOCIAZPCWZPU-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- RJROWIATTDKDPU-UHFFFAOYSA-N n-[4-[1,5-bis(hydroxymethyl)-8-oxabicyclo[3.2.1]octa-3,6-dien-3-yl]-2-(4,4-dimethylcyclohexen-1-yl)phenyl]-5-cyano-1h-imidazole-2-carboxamide Chemical compound C1C(C)(C)CCC(C=2C(=CC=C(C=2)C=2CC3(OC(C=C3)(CO)C=2)CO)NC(=O)C=2NC(=CN=2)C#N)=C1 RJROWIATTDKDPU-UHFFFAOYSA-N 0.000 description 1
- 239000011858 nanopowder Substances 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- UCUUFSAXZMGPGH-UHFFFAOYSA-N penta-1,4-dien-3-one Chemical compound C=CC(=O)C=C UCUUFSAXZMGPGH-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108010072897 transcription factor Brn-2 Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- AJSTXXYNEIHPMD-UHFFFAOYSA-N triethyl borate Chemical compound CCOB(OCC)OCC AJSTXXYNEIHPMD-UHFFFAOYSA-N 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- HCARCYFXWDRVBZ-UHFFFAOYSA-N undecan-3-ol Chemical compound CCCCCCCCC(O)CC HCARCYFXWDRVBZ-UHFFFAOYSA-N 0.000 description 1
- YNMZZHPSYMOGCI-UHFFFAOYSA-N undecan-3-one Chemical compound CCCCCCCCC(=O)CC YNMZZHPSYMOGCI-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Description
本出願は、米国特許仮出願シリアル番号第60/980623号(2007年10月17日出願)(その全体が本明細書に参考として組み込まれる)からの優先権を主張する。
本発明は、プロテインチロシンキナーゼ阻害剤として機能する新規化合物に関する。より具体的には、本発明は、c−fmsキナーゼの阻害剤として機能する新規化合物に関する。
式中、各R4は独立して、H、F、Cl、Br、I、OH、OCH3、OCH2CH3、SC(1〜4)アルキル、SOC(1〜4)アルキル、SO2C(1〜4)アルキル、−C(1〜3)アルキル、CO2Rd、CONReRf、C≡CRg又はCNであり、
式中、RdはH又は−C(1〜3)アルキルであり、
ReはH又は−C(1〜3)アルキルであり、
RfはH又は−C(1〜3)アルキルであり、及び
RgはH、−CH2OH又は−CH2CH2OHであり、
R2は、シクロアルキル、スピロ置換シクロアルケニル、チオフェニル、ジヒドロスルホノピラニル、フェニル、フラニル、テトラヒドロピリジル、又はジヒドロピラニルであり、そのいずれもが独立して、以下:塩素、フッ素、ヒドロキシ基、C(1〜3)アルキル、又はC(1〜4)アルキル;それぞれ1つ又は2つによって置換されていてよく、
ZはH、F、Cl又はCH3であり、
JはCH又はNであり、
Xは
式中、各R4は独立して、H、F、Cl、Br、I、OH、OCH3、OCH2CH3、SC(1〜4)アルキル、SOC(1〜4)アルキル、SO2C(1〜4)アルキル、−C(1〜3)アルキル、CO2Rd、CONReRf、C≡CRg又はCNであり、
式中、RdはH又は−C(1〜3)アルキルであり、
ReはH又は−C(1〜3)アルキルであり、
RfはH又は−C(1〜3)アルキルであり、及び
RgはH、−CH2OH又は−CH2CH2OHであり、
R2は、シクロアルキル、スピロ置換シクロアルケニル、チオフェニル、ジヒドロスルホノピラニル、フェニル、フラニル、テトラヒドロピリジル又はジヒドロピラニルであり、そのいずれもが独立して、以下:塩素、フッ素、ヒドロキシ基、C(1〜3)アルキル又はC(1〜4)アルキル;それぞれ1つ又は2つによって置換されていてよく、
ZはH、F、Cl又はCH3であり、
JはCH又はNであり、
Xは
式中、RwはH、−C(1〜4)アルキル、−CO2C(1〜4)アルキル、−CONH2、−CONHC(1〜4)アルキル、−CON(C(1〜4)アルキル)2又は−COC(1〜4)アルキルである、化合物又はそれらの溶媒和物、水和物、互変異性体若しくは薬剤として許容される塩に関する。
JはCH又はNであり、
JはCH又はNであり、
JはCH又はNであり、
JはCH又はNであり、
Xは、
式中、RwはH、−C(1〜4)アルキル、−CO2C(1〜4)アルキル、−CONH2、−CONHC(1〜4)アルキル、−CON(C(1〜4)アルキル)2又は−COC(1〜4)アルキルである、化合物、並びにそれらの溶媒和物、水和物、互変異性体及び薬剤として許容される塩である。
Xは、
4−シアノ−1H−イミダゾール−2−カルボン酸[2−シクロヘキセ−1−エニル−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド;
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド塩酸塩;4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミドメタンスルホン酸塩;及び
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド(1S)−(+)−10−カンファースルホン酸塩;からなる群から選択される。最も好ましくは、化合物は、4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド塩酸塩である。
用語「アルキル」は、特に指示がない限り12個以下の炭素原子、好ましくは6個以下の炭素原子からなる直鎖及び分岐鎖両方のラジカルを意味し、メチル、エチル、プロピル、イソプロピル、ブチル、イソブチル、sec−ブチル、tert−ブチル、ペンチル、イソペンチル、ヘキシル、イソヘキシル、ヘプチル、オクチル、2,2,4−トリメチルペンチル、ノニル、デシル、ウンデシル及びドデシルが挙げられるがこれらに限定されない。
式Iの化合物は、プロテインチロシンキナーゼの新規の強力な阻害剤、例えば、c−fmsを表し、これらのキナーゼの作用に起因する疾患の予防及び治療において有用であり得る。
更に、本発明の化合物は、1種以上の多形体又は非晶質結晶性(amorphous crystalline)形態を有してよく、かつ本発明の範囲に含まれるものとする。加えて、化合物は、例えば水(即ち、水和物)又は一般有機溶媒と共に溶媒和物を形成してよい。本明細書で使用するとき、用語「溶媒和物」は、本発明の化合物と1種以上の溶媒分子との物理的会合を意味する。この物理的会合は、水素結合を含む、イオン結合及び共有結合の度合いが変化することを伴う。特定の場合には、溶媒和物は、例えば、1種以上の溶媒分子が結晶固形物の結晶格子内に組み込まれた場合に、単離することができる。用語「溶媒和物」は、溶液相及び分離可能な溶媒和物の両方を包含することを意図する。好適な溶媒和物の非限定例としては、エタノレート、メタノレートなどが挙げられる。
式9−2(式中、Rcは−CNではない)のイミダゾールについては、これらは、アルキルリチウムなどの好適な塩基で脱プロトン化し、続いて、有機マグネシウム種について前述したように、求電子体と反応させることによって、式9−4のイミダゾールへと直接変換してよい。好ましい条件は、THF中−78℃でn−ブチルリチウムにてイミダゾールを処理すること、及び得られた有機リチウム種をエチルクロロホルメートでクエンチすることである。(例えば、「テトラヒドロン・レターズ(Tetrahedron Lett.)」(1988年)、29号、3411〜3414ページ)を参照のこと。)
次に、式9−4のエステルを、1当量の金属水酸化物(MOH)水溶液、好ましくはエタノール又はメタノールなどの好適な溶媒中で水酸化カリウムを使用して、式9−5のカルボン酸(MはHである)又はカルボキシレート塩(carboxylate salts)(MはLi、Na、又はK)へと加水分解してよい。式9−5(式中、Rqは−CONH2である)の化合物の合成は、最初に式9−4(式中、Rcは−CNである)の化合物を、カリウムエトキシドなどの適切なアルコキシドによって処理して、シアノ基をイミデート基へと変換し(ピナー(Pinner)反応)、続いてエステル及びイミデート基の両方を、2当量の金属水酸化物水溶液で加水分解することにより行なう。
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−4−[(3−エキソ)−3−ヒドロキシ−1,5−ビス−メトキシメチル−8−オキサ−ビシクロ[3.2.1]オクト−6−エン−3−イル]−フェニル]−アミド
4−シアノ−1H−イミダゾール−2−カルボン酸[4−ブロモ−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド(本実施例の工程(c)のようにして調製、204mg、0.511mmol)の無水THF7mL溶液へ、アルゴン下−78℃にて、塩化イソプロピルマグネシウムの溶液(THF中2.0M、321μL、0.641mmol)を添加した。反応物を室温まで暖め、75分間攪拌し、次に、再度−78℃まで冷却した。tert−ブチルリチウムの溶液(ペンタン中1.7M、900μL、1.53mmol)を添加し、20分間撹拌後、1,5−ビス−メトキシメチル−8−オキサ−ビシクロ[3.2.1]オクト−6−エン−3−オンの3.5mL THF溶液(前工程と同様に調製、141mg、0.664mmol)を1.5分以上かけて添加した。次は、混合物を、−78℃にて30分間攪拌し、次に室温にて16時間攪拌した。反応物を4mLのNH4Cl飽和水溶液でクエンチし、EtOAc(50mL)中に注ぎ込み、水(10mL)及びブライン(10mL)で洗浄し、乾燥させ(Na2SO4)、濃縮して、292mgの固体を得た。この残留物を4mLのMeCN中にて懸濁させ、ろ過し、MeCNで洗浄し(1mLにて2回)、ろ液を濃縮して230mgの固体を得た。20−gのシリカゲルSPEカラム(10〜60% EtOAc−DCM)上クロマトグラフィーにて、ガラスを得て、EtOAc−ヘキサン(1:1)から濃縮後、表題化合物(32.4mg、12%)を白色固体として得た。1H−NMR(CDCl3;400MHz):δ9.62(s,1H)、8.37(d,1H,J=8.6Hz)、7.69(s,1H)、7.53(dd,1H,J=8.6Hz,2.3Hz)、7.35(d,1H,J=2.3Hz)、6.43(s,2H)、5.74〜5.78(m,1H)、3.59(s,4H)、3.40(s,6H)、2.40(d,2H,J=14.7Hz)、2.25〜2.33(m,2H)、2.08〜2.11(m,2H)、1.96(d,2H,J=14.7Hz)、1.58(t,2H,J=6.2Hz)、1.10(s,6H)。質量スペクトル(ESI,m/z):C30H36N4O5、515.3(M−H20+H)について計算し、結果は515.0であった。
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−4−((3−エキソ)−3−ヒドロキシ−1,5−ビス−ヒドロキシメチル−8−オキサ−ビシクロ[3.2.1]オクト−6−エン−3−イル)−フェニル]−アミド
4−シアノ−1H−イミダゾール−2−カルボン酸[4−[(3−エンド)−3−ヒドロキシ−1,5−ビス−(tert−ブチル−ジメチル−シラニルオキシメチル)−8−オキサ−ビシクロ[3.2.1]オクト−6−エン−3−イル]−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド(前工程と同様に調製、125mg、0.171mmol)及びフッ化テトラブチルアンモニウム一水和物(TBAF・H2O)(357mg、1.36mmol)の3mL THF中混合物を60℃にて1時間攪拌した。室温まで冷却した後、混合物をEtOAc(50mL)で処理し、H2O(10mL)、NH4Cl飽和水溶液(10mLにて2回)及びブライン(10mL)で洗浄した。有機層をNa2SO4上で乾燥させ、減圧下で濃縮した。残留物をDCMと共に粉砕し、表題化合物(72mg、84%)を白色固体として得た。1H−NMR(CD3OD;400MHz):δ8.15(d,1H,J=8.6Hz)、7.99(s,1H)、7.38(dd,1H,J=8.6,2.3Hz)、7.31(d,1H,J=2.3Hz)、6.18(s,2H)、5.73(m,1H)、3.68(s,4H)、2.31(m,2H)、2.12(d,2H,J=14.7Hz)、2.07(m,2H)、1.79(d,2H,J=14.7Hz)、1.59(t,2H,J=6.3Hz)、1.09(s,6H)。
4−シアノ−1H−イミダゾール−2−カルボン酸[4−(1,5−ビス−ヒドロキシメチル−8−オキサ−ビシクロ[3.2.1]オクタ−2,6−ジエン−3−イル)−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド
4−シアノ−1H−イミダゾール−2−カルボン酸[4−[(3−エキソ)−1,5−ビス−ヒドロキシメチル−8−オキサ−ビシクロ[3.2.1]オクト−3−イル]−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド
4−シアノ−1−(2−トリメチルシラニル−エトキシメチル)−1H−イミダゾール−2−カルボン酸[4−[(3−エキソ)−1,5−ビス−(tert−ブチル−ジメチル−シラニルオキシメチル)−8−オキサ−ビシクロ[3.2.1]オクト−3−イル]−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド(前工程と同様に調製、400mg、0.471mmol)及びフッ化テトラブチルアンモニウム一水和物(739mg、2.83mmol)の5mL THF中混合物を50℃にて16時間攪拌した。室温まで冷却した後、混合物をEtOAc(50mL)で処理し、H2O(10mL)、NH4Cl飽和水溶液(10mLにて2回)及びブライン(10mL)で洗浄した。有機層をNa2SO4上で乾燥させ、減圧下で濃縮した。残留物をDCMと共に粉砕し、表題化合物(203mg、88%)を白色固体として得た。1H−NMR(CD3OD;400MHz):δ8.11(d,1H,J=8.6Hz)、7.99(s,1H)、7.20(dd,1H,J=8.6,2.3Hz)、7.11(d,1H,J=2.3Hz)、5.72(m,1H)、3.62(d,2H,J=11.7Hz)、3.52(d,2H,J=11.7Hz)、3.21(m,1H)、2.30(m,2H)、2.07(m,2H)、1.84−1.97(m,4H)、1.63〜1.71(m,4H)、1.59(t,2H,J=6.3Hz)、1.08(s,6H)。質量スペクトル(ESI,m/z):C28H34N4O4、491.3(M+H)について計算し、結果は491.1であった。
4−シアノ−1H−イミダゾール−2−カルボン酸[4−[(3−エンド)−1,5−ビス−ヒドロキシメチル−8−オキサ−ビシクロ[3.2.1]オクト−3−イル]−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド
表題化合物は、4−シアノ−1−(2−トリメチルシラニル−エトキシメチル)−1H−イミダゾール−2−カルボン酸[4−[(3−エンド)−1,5−ビス−(tert−ブチル−ジメチル−シラニルオキシメチル)−8−オキサ−ビシクロ[3.2.1]オクト−3−イル]−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド(前工程と同様に調製、185mg、0.218mmol)及びテトラブチル−フッ化アンモニウム一水和物(342mg、1.31mmol)を使用し、実施例4、工程(g)の手順によって調製した。シリカゲルクロマトグラフィー(1〜5% MeOH/DCM)によって、表題化合物(100mg、93%)を薄い茶色の油として得た。1H−NMR(CD3OD;400MHz):δ8.10(d,1H,J=8.6Hz)、7.98(s,1H)、7.21(dd,1H,J=8.6,2.0Hz)、7.10(d,1H,J=2.0Hz)、5.72(m,1H)、3.63(d,2H,J=11.6Hz)、3.50(d,2H,J=11.6Hz)、2.91(m,1H)、2.30(m,2H)、1.93〜2.09(m,6H)、1.55〜1.73(m,6H)、1.08(s,6H)。質量スペクトル(ESI,m/z):C28H34N4O4、491.3(M+H)について計算し、結果は491.1であった。
4−シアノ−1H−イミダゾール−2−カルボン酸[4−[(3−エンド)−1,5−ビス−メトキシメチル−8−オキサ−ビシクロ[3.2.1]オクト−3−イル]−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド
表題化合物は、4−シアノ−1−(2−トリメチルシラニル−エトキシメチル)−1H−イミダゾール−2−カルボン酸[4−[(3−エンド)−1,5−ビス−メトキシメチル−8−オキサ−ビシクロ[3.2.1]オクト−3−イル]−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド(前工程と同様に調製、150mg、0.231mmol)及びテトラブチル−フッ化アンモニウム一水和物(181mg、0.693mmol)を使用し、実施例4、工程(g)の手順によって調製した。シリカゲルクロマトグラフィー(25% EtOAc/DCM)によって、表題化合物(102mg、85%)を白色固体として得た。質量スペクトル(ESI,m/z):C12H13BrN2O、281.0(M+H)について計算し、結果は281.2であった。1H−NMR(CD3OD;400MHz):δ8.11(d,1H,J=8.6Hz)、7.98(s,1H)、7.20(dd,1H,J=8.6,2.3Hz)、7.09(d,1H,J=2.3Hz)、5.71(m,1H)、3.46(d,2H,J=10.1Hz)、3.40(d,2H,J=10.1Hz)、3.40(m,6H)、2.90(m,1H)、2.29(m,2H)、2.17(dd,1H,J=13.5,6.7Hz)、2.06(m,2H)、1.80〜1.89(m,2H)、1.67〜1.76(m,2H)、1.58−1.64(m,2H)、1.58(t,2H,J=6.3Hz)、1.08(s,6H)。質量スペクトル(ESI,m/z):C30H38N4O4、519.3(M+H)について計算し、結果は519.0であった。
4−シアノ−1H−イミダゾール−2−カルボン酸[4−((3−エキソ)−1,5−ビス−ヒドロキシメチル−8−オキサ−ビシクロ[3.2.1]オクト−3−イル)−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド
表題化合物は、4−シアノ−1−(2−トリメチルシラニル−エトキシメチル)−1H−イミダゾール−2−カルボン酸[4−((3−エキソ)−1,5−ビス−メトキシメチル−8−オキサ−ビシクロ[3.2.1]オクト−3−イル)−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド(前工程と同様に調製、150mg、0.231mmol)及びフッ化テトラブチルアンモニウム一水和物(181mg、0.693mmol)を使用し、実施例4、工程(g)の手順によって調製した。シリカゲルクロマトグラフィー(25% EtOAc/DCM)によって、表題化合物(86.4mg、72%)を白色固体として得た。1H−NMR(CD3OD;400MHz):δ8.11(d,1H,J=8.5Hz)、7.98(s,1H)、7.19(dd,1H,J=8.5,2.0Hz)、7.09(d,1H,J=2.0Hz)、5.73(m,1H)、3.45(d,2H,J=10.1Hz)、3.41(d,2H,J=10.1Hz)、3.39(s,6H)、3.16(m,1H)、2.31(m,2H)、2.07(m,2H)、1.88〜1.96(m,2H)、1.76〜1.85(m,2H)、1.65−1.76(m,4H)、1.59(t,2H,J=6.3Hz)、1.08(s,6H)。質量スペクトル(ESI,m/z):C30H38N4O4、519.3(M+H)について計算し、結果は519.1であった。
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−4−[(3−エキソ)−3−ヒドロキシ−1,5−ビス−ヒドロキシメチル−8−オキサ−ビシクロ[3.2.1]オクト−3−イル]−フェニル]−アミド
4−シアノ−1H−イミダゾール−2−カルボン酸[4−[1,5−ビス−(tert−ブチル−ジメチル−シラニルオキシメチル)−3−エンド−ヒドロキシ−8−オキサ−ビシクロ[3.2.1]オクト−3−イル]−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド(前工程にて調製、110mg、1.49mmol)のTHF(1mL)溶液をTBAF.H20(150mg、5.75mmol)にて処理し、混合物を60℃にて8時間攪拌した。反応物をEtOAc(10mL)で希釈し、H2O(10mLにて2回)及びブライン(10mL)で洗浄し、Na2SO4上で乾燥し、濃縮した。固形物はEt2Oと共に粉砕し及びろ過して、50mg(69%)の白色固体を得た。1H NMR(400MHz、DMSO−d6)δppm 14.21(brs,1H)、9.73(brs,1H)、8.31(s,1H)、7.90(d,J=8.6Hz,1H)、7.35(dd,J=8.6,1.9Hz,1H)、7.27(d,J=1.9Hz,1H)、5.66(m,1H)、4.92(s,1H)、4.61(t,J=5.8Hz,2H)、3.33〜3.44(m,4H)、2.22〜2.29(m,4H)、1.91〜1.98(m,4H)、1.70〜1.76(m,2H)、1.55−1.59(m,2H)、1.47〜1.52(m,2H)、1.00(s,6H)。質量スペクトル(ESI,m/z):C28H34N4O5、507.2(M+H)について計算し、結果は507.1であった。
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−4−((3−エキソ)−3−ヒドロキシ−1,5−ジメチル−8−オキサ−ビシクロ[3.2.1]オクト−6−エン−3−イル)−フェニル]−アミド
3−(3−エキソ)−[4−[(4−シアノ−1H−イミダゾール−2−カルボニル)−アミノ]−3−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−(3−エキソ)−3−ヒドロキシ−1,5−ジメチル−8−アザ−ビシクロ[3.2.1]オクト−6−エン−8−カルボン酸メチルエステル
表題化合物は、4−シアノ−1H−イミダゾール−2−カルボン酸[4−ブロモ−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド(実施例1、工程(c)と同様に調製)及び1,5−ジメチル−3−オキソ−8−アザ−ビシクロ[3.2.1]オクト−6−エン−8−カルボン酸メチルエステル(前工程と同様に調製)を使用して、実施例1、工程(f)に記載されているようにして調製した。1H−NMR(CDCl3;400MHz):δ9.60(s,1H)、8.16(d,1H,J=8.6Hz)、7.63(s,1H)、7.17(dd,1H,J=8.6,2.0Hz)、7.12(d,1H,J=2.0Hz)、5.98(s,2H)、5.68(brs,1H)、3.69(s,3H)、3.24(brs、1H)、2.45(d,2H,J=15.2Hz)、2.20(m,2H)、2.00(m,2H)、1.81(d,2H,J=15.2Hz)、1.59(s,6H)、1.48(m,2H)、1.03(s,6H)。質量スペクトル(ESI,m/z):C30H35N5O4、530.2(M+H)について計算し、結果は530.2であった。
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−4−[(3−エキソ)−3−ヒドロキシ−1,5−ジメチル−6−エキソ,7−エキソ−(ジメチルメチレンジオキシ)−ビシクロ[3.2.1]オクト−3−イル]−フェニル]−アミド
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−4−(3−エキソ)−3,6−エキソ,7−エキソ−トリヒドロキシ−1,5−ジメチル−8−オキサ−ビシクロ[3.2.1]オクト−3−イル)−フェニル]−アミド
4−シアノ−1−(2−トリメチルシラニル−エトキシメチル)−1H−イミダゾール−2−カルボン酸[4−(4,4−ジ−tert−ブチル−(9−エキソ)−9−ヒドロキシ−1,7−ジメチル−3,5,11−トリオキサ−4−シラ−トリシクロ[5.3.1.02,6]ウンデカ−9−イル)−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド(前工程と同様に調製、250mg、0.321mg)のDMF(2mL)溶液へと、固形TBAF水和物(419mg、1.60mmol)を添加した。得られた混合物を50℃にて終夜攪拌した。反応混合物を室温まで冷却させ、水(10mL)で処理した。生成物をEtOAcで抽出した(10mLで3回)。そのEtOAc層を合一させ、乾燥させ(Na2SO4)、濃縮した。得られた残留物をシリカゲル(50% EtOAc/ヘキサン−100% EtOAc)上で精製し、表題化合物(115mg、55%)を得た。1H−NMR(CD3OD;400MHz):δ8.18(d,1H,J=8.6Hz)、8.01(s,1H)、7.37(dd,1H,J=8.6,2.2Hz)、7.30(m,1H)、5.75(brs,1H)、4.64(s,2H)、2.33(m,2H)、2.09(m,2H)、2.00(d,2H,J=14.9Hz)、1.92(d,2H,J=14.9Hz)、1.61(t,2H,J=6.4Hz)、1.30(s,6H)、1.10(s,6H)。質量スペクトル(APCI,m/z):C28H34N4O5、507.2(M+H)について計算し、結果は507.3であった。
4−シアノ−1H−イミダゾール−2−カルボン酸[4−(3−エンド)−(6−エキソ,7−エキソ−ジヒドロキシ−1,5−ジメチル−8−オキサ−ビシクロ[3.2.1.]オクト−3−イル)−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド
4−シアノ−1H−イミダゾール−2−カルボン酸[4−シス−(2−シス,6−シス−ビス−ヒドロキシメチル−2,6−ジメチル−テトラヒドロ−ピラン−4−イル)−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド(A)及び4−シアノ−1H−イミダゾール−2−カルボン酸[4−トランス−(2−シス,6−シス−ビス−ヒドロキシメチル−2,6−ジメチル−テトラヒドロ−ピラン−4−イル)−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−フェニル]−アミド(B)
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド
4−シアノ−1−(2−トリメチルシラニル−エトキシメチル)−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド(上記実施例と同様に調製、17.6g、0.0290mol)のDMF(30mL)溶液へと、固形TBAF水和物(16.6g、0.0630mol)を添加した。得られた混合物を70℃にて一晩加熱した。反応混合物を室温まで冷却し、EtOAc(200mL)と水(200mL)との間で分画した。有機層を分離し、水層をEtOAcで洗浄し(100mLで3回)、有機層を合一させ、乾燥させ(Na2SO4)、濃縮した。得られた残留物を高真空下で乾燥させて、残留DMFを除去した。残留物は、シリカゲル(0〜50% EtOAc/ヘキサン)上で精製した。次に、得られた固形物を25%エーテル/ヘキサン中にて懸濁させ、10分間超音波で分解させた。生成物を吸引濾過で収集し、真空オーブン中60℃にて12時間乾燥させ、表題化合物を白色固体(10.2g、75%)として得た。1H−NMR(DMSO;400MHz):δ14.26(s,1H)、10.02(s,1H)、8.32(s,1H)、8.12(d,1H,J=8.3Hz)、7.24(d,1H,J=8.3Hz)、5.86(brs,1H)、3.23(m,1H)、2.40(m,2H)、1.91(m,2H)、1.74(dd,2H,J=12.9,3.3Hz)、1.48(m,4H)、1.30(s,6H)、1.15(s,6H)、0.96(s,6H)。質量スペクトル(ESI,m/z):C27H35N5O2、462.2(M+H)について計算し、結果は462.3であった。
4−シアノ−1H−イミダゾール−2−カルボン酸[2−シクロヘキセ−1−エニル]−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド
実施例15、工程(h)に記載されているように、表題化合物は、4−シアノ−1−(2−トリメチルシラニル−エトキシメチル)−1H−イミダゾール−2−カルボン酸[2−シクロヘキセ−1−エニル−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミドから調製した。1H−NMR(CDCl3;400MHz):δ12.48(brs,1H)、9.72(s,1H)、8.59(d,1H,J=8.3Hz)、7.74(s,1H)、7.12(d,1H,J=8.3Hz)、6.06(brs,1H)、3.27(m,1H)、2.45(m,2H)、2.33(m,2H)、1.85(m,6H)、1.57(t,2H,J=12.8Hz)、1.35(s,6H)、1.26(s,6H)。質量スペクトル(ESI,m/z):C25H31N5O2、434.2(M+H)について計算し、結果は434.2であった。
4−シアノ−1H−イミダゾール−2−カルボン酸[6−[(3−エキソ)−6−エキソ,7−エキソ−(イソプロピリジンジオキシ)−1,5−ジメチル−8−オキサ−ビシクロ[3.2.1]オクト−3−イル]−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−ピリジン−3−イル]−アミド
表題化合物は、4−シアノ−1−(2−トリメチルシラニル−エトキシメチル)−1H−イミダゾール−2−カルボン酸[6−[(3−エキソ)−6−エキソ,7−エキソ−(イソプロピリジンジオキシ)−1,5−ジメチル−8−オキサ−ビシクロ[3.2.1]オクト−3−イル]−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−ピリジン−3−イル]−アミド(前工程と同様に調製)を使用し、実施例2、工程(b)の手順に従って調製した。1H−NMR(CDCl3;400MHz):δ11.52(brs,1H)、9.75(brs,1H)、8.67(d,1H,J=8.8Hz)、7.73(s,1H)、7.23(d,1H,J=8.8Hz)、6.00−5.95(m,1H)、4.35(s,2H)、3.38−3.29(m,1H)、2.54−2.46(m,2H)、2.38−2.30(m,2H)、2.17−2.11(m,2H)、2.05−1.98(m,2H)、1.64−1.60(m,2H)、1.47(s,3H)、1.35(s,6H)、1.15(s,3H)、1.11(s,6H)。質量スペクトル(APCI,m/z):C30H37N5O4、532.3(M+H)について計算し、結果は532.3であった。
4−シアノ−1H−イミダゾール−2−カルボン酸[6−[(3−エキソ)−(6−エキソ,7−エキソ−ジヒドロキシ−1,5−ジメチル−8−オキサ−ビシクロ[3.2.1]オクト−3−イル)−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−ピリジン−3−イル]−アミドトリフルオロ酢酸塩及び4−シアノ−1H−イミダゾール−2−カルボン酸[6−[(3−エンド)−(6−エキソ,7−エキソ−ジヒドロキシ−1,5−ジメチル−8−オキサ−ビシクロ[3.2.1]オクト−3−イル)−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−ピリジン−3−イル]−アミドトリフルオロ酢酸塩
4−シアノ−1H−イミダゾール−2−カルボン酸[2−シクロヘキセ−1−エニル−6−[(3−エキソ)−(6−エキソ,7−エキソ−ジヒドロキシ−1,5−ジメチル−8−オキサ−ビシクロ[3.2.1]オクト−3−イル]−ピリジン−3−イル]−アミドトリフルオロ酢酸塩及び4−シアノ−1H−イミダゾール−2−カルボン酸[2−シクロヘキセ−1−エニル−6−[(3−エンド)−(6−エキソ,7−エキソ−ジヒドロキシ−1,5−ジメチル−8−オキサ−ビシクロ[3.2.1]オクト−3−イル]−ピリジン−3−イル]−アミドトリフルオロ酢酸塩
4−シアノ−1H−イミダゾール−2−カルボン酸[(4−シス)−(2−シス,6−シス−ビス−ヒドロキシメチル−2,6−ジメチル−テトラヒドロ−ピラン−4−イル)−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−ピリジン−3−イル]−アミドトリフルオロ酢酸塩及び4−シアノ−1H−イミダゾール−2−カルボン酸[(4−トランス)−(2−シス,6−シス−ビス−ヒドロキシメチル−2,6−ジメチル−テトラヒドロ−ピラン−4−イル)−2−(4,4−ジメチル−シクロヘキセ−1−エニル)−ピリジン−3−イル]−アミドトリフルオロ酢酸塩
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−1,1−ジオキソ−ヘキサヒドロ−1λ6−チオピラン−4−イル)−ピリジン−3−イル]−アミド
表題化合物は、実施例1、工程(c)の手順に従って、4−シアノ−1−(2−トリメチルシラニル−エトキシメチル)−1H−イミダゾール−2−カルボン酸[2,(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−1,1−ジオキソ−ヘキサヒドロ−1λ6−チオピラン−4−イル)−ピリジン−3−イル]−アミド(前工程と同様に調製)から調製し、続いてNaHCO3と共に遊離塩基を形成した。1H−NMR(CDCl3;400MHz):δ9.76(s,1H)、8.77(d,1H,J=9.2Hz)、7.74(s,1H)、7.40(d,1H,J=9.2Hz)、6.02−5.95(m,1H)、3.48−3.37(m,1H)、2.60−2.42(m,4H)、2.20−2.13(m,2H)、2.03−1.95(m,2H)、1.68(s,6H)、1.67−1.62(m,2H)、1.43(s,6H)、1.13(s,6H)。質量スペクトル(ESI,m/z):C27H35N5O3S、510.3(M+H)について計算し、結果は510.3であった。
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−4−(2,2,6,6−テトラメチル−1,1−ジオキソ−ヘキサヒドロ−1λ6−チオピラン−4−イル)−フェニル]−アミド
表題化合物は、実施例1、工程(c)の手順に従って、4−シアノ−1−(2−トリメチルシラニル−エトキシメチル)−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−4−(2,2,6,6−テトラメチル−1,1−ジオキソ−ヘキサヒドロ−1λ6−チオピラン−4−イル)−フェニル]−アミド(前工程と同様に調製)から調製した。1H−NMR(CDCl3;400MHz):δ9.62(s,1H)、8.41(d,1H,J=8.0Hz)、7.73(s,1H)、7.41(d,1H,J=8.0Hz)、7.05(d,1H,J=2.4Hz)、5.81−5.75(m,1H)、3.25−3.14(m,1H)、2.55−2.42(m,2H)、2.34−2.26(m,2H)、2.15−2.08(m,2H)、1.93−1.85(m,2H)、1.66(s,6H)、1.64−1.57(m,2H)、1.43(s,6H)、1.12(s,6H)。質量スペクトル(APCI,m/z):C28H36N4O3S、509.3(M+H)について計算し、結果は509.1であった。
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド塩酸塩(hydrochloride salt)
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミドメタンスルホン酸塩
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド(1S)−(+)−10−カンファースルホン酸塩
N−(4−(8−オキサビシクロ[3.2.1]オクタ−2,6−ジエン−3−イル)−2−(4,4−ジメチルシクロヘキセ−1−エニル)フェニル)−4−シアノ−1H−イミダゾール−2−カルボキサミド(A)及びN−(4−(8−オキサビシクロ[3.2.1]オクタ−3,6−ジエン−3−イル)−2−(4,4−ジメチルシクロヘキセ−1−エニル)フェニル)−4−シアノ−1H−イミダゾール−2−カルボキサミド(B)
4−シアノ−N−(2−(4,4−ジメチルシクロヘキセ−1−エニル)−4−((3−エキソ)−3−ヒドロキシ−8−オキサビシクロ[3.2.1]オクト−6−エン−3−イル)フェニル)−1H−イミダゾール−2−カルボキサミド
4−シアノ−N−(2−(4,4−ジメチルシクロヘキセ−1−エニル)−4−[(3−エキソ)−3−ヒドロキシ−(2−エンド−4−エンド−ジメチル)−8−オキサビシクロ[3.2.1]オクト−6−エン−3−イル)フェニル])−1H−イミダゾール−2−カルボキサミド
4−シアノ−N−(2−(4,4−ジメチルシクロヘキセ−1−エニル)−4−[(3−エキソ)−3−ヒドロキシ−(2−エンド,4−エンド−ジメチル)−1,5−ジメチル−8−オキサビシクロ[3.2.1]オクタン−3−イル)フェニル]−1H−イミダゾール−2−カルボキサミド
4−シアノ−N−(2−(4,4−ジメチルシクロヘキセ−1−エニル)−4−[(3−エキソ)−3−ヒドロキシ−(2−エンド,4−エンド−ジメチル)−1,5−ジメチル−8−オキサビシクロ[3.2.1]オクト−6−エン−3−イル)フェニル)−1H−イミダゾール−2−カルボキサミド
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド硫酸塩
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド(24.8mg、0.0537mmol)のアセトニトリル(1.0mL)中懸濁液(実施例15と同様に調製)を加熱して溶液を得た。前記溶液へと、水(0.5mL)中濃硫酸(0.0062mL)の溶液を室温にて添加した。溶液は、窒素ガス(約1.0mL)を流しながら、蒸発により濃縮させた。次に、溶液を室温で密封されたバイアル瓶内に一晩放置した。次に、得られた結晶をろ過により収集し、空気乾燥した。白色固体は、粉末X線回折(PXRD)、示差走査熱量計(DSC)、熱重量分析(Thremogravimetric Analysis)(TGA)、及び単結晶X線回折にて同定した。硫酸塩は、DSCにて、241℃で最大吸熱を示した。硫酸塩生成物のPXRDは、図1に示されており、突出ピークが下表に示されている。
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミドナトリウム塩(形態A)
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド(23.1mg、0.0500mmol)のエタノール(1.0mL)懸濁液へ、実施例15と同様に、水酸化ナトリウム(1.0N;0.055mL;0.055mmol)の溶液を添加した。溶液は、開放したバイアル瓶内にて室温で蒸発させた。白色結晶性固体を得、PXRD及びTGAにより同定した(重量損失6.1%)。ナトリウム塩の形態AのPXRDを図2に示し、突出ピークを下表に示す。
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミドナトリウム塩(形態B)
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド(26.1mg、0.0556mmol)のアセトニトリル(1.0mL)懸濁液へ、実施例15と同様に、水酸化ナトリウム(1.0N;0.062mL;0.062mmol)の溶液を添加して、濁った溶液を得た。次に、水(0.44mL)を添加して、溶液を透明にさせた。次に、揮発物を蒸発させて、非晶質固体を得た。次に、固体をジエチルエーテル(1.0mL)及びプロピレングリコール(0.009mL)中に溶解させた。ヘプタン(2.0mL)を添加して、混合物を乳化させた。混合物を開放したバイアル瓶内にて一晩放置した。結晶性物質が形成され、これは収集され、PXRD及びTGAにて同定された(重量損失31.0%)。ナトリウム塩の形態BのPXRDを図3に示し、突出ピークを下表に示す。
A.蛍光偏光競合免疫測定法
自己リン酸化、蛍光偏光競合免疫測定法を使用して、式Iの選択化合物によって示されるc−fms阻害の潜在能を決定した。アッセイは、ブラック96ウェルマイクロプレート(LJLバイオシステムズ(BioSystems))内で実施した。使用したアッセイバッファーは、100mM 4−(2−ヒドロキシエチル)ピペラジン1−エタンスルホン酸(HEPES)、pH7.5、1mM 1,4−ジチオ−DL−トレイトール(DTT)、0.01%(v/v)ツウィーン(Tween)−20であった。化合物は、アッセイ直前に、4%ジメチルスルホキシド(DMSO)を含有するアッセイバッファー中にて希釈した。各ウェルへと、5μLの化合物を添加し、続いて、33nM c−fms(ジョンソン&ジョンソンPRD)及び16.7mM MgCl2(シグマ(Sigma))をアッセイバッファー中に含有する3μLの混合物を添加した。キナーゼ反応は、2μLの5mM ATP(シグマ(Sigma))をアッセイバッファー中に添加することによって開始された。アッセイでの終濃度は、10nM c−fms、1mM ATP、5mM MgCl2、2% DMSOであった。対照反応は、次のようにして各プレートにて実施した:陽性及び陰性対照ウェルにおいて、アッセイバッファー(DMSO中4%で調製)を化合物と置き換えた。加えて、陽性対照ウェルに、1.2μLの50mMエチレンジアミン4酢酸(EDTA)を加えた。
マクロファージは、マウスの骨髄を10% FCS及び50ng/mL組み替えマウスCSF−1を微生物用ディッシュに添加したアルファ−MEM内にて培養することによって得た。6日目に、マクロファージを皿から分離し、洗浄し、10% FCSを含有するアルファ−MEM 1mLあたり50000個の細胞へと再懸濁した。96ウェル培養プレートの1ウェルあたり、100μLの細胞懸濁液を分配した。ウェルには更に、15ng/mL CSF−1、3μMインドメタシン、及び3倍希釈の一連の試験化合物を含有する培地50μLを添加した。細胞は、30時間37℃、5% CO2で培養した。最後の6時間は、培養液には更に、1:500希釈のブロモデオキシウリジン(BrDU)を含有する30μLの培地を添加した。培養期間の最後に、プレートを1000RPMで1分間回転し、130μLの培地をピペットで除去し、150μLの固定液で室温で1時間の間交換した。次に、固定液をプレートから取り除き、プレートを空気乾燥させた。固定し、乾燥させた細胞へのBrDUの取り込みは、特異的ELISAを使用して定量化した。
目的:雌のルイスラットに多発性関節炎を生じさせ、続いて連鎖球菌細胞壁(SCW)構成成分の腹腔内投与を行なった。このモデルは、補体及び好中球依存性であり、回復する、急性の非びらん性期(3〜7日)を有する。慢性びらん期は、約10日で開始され、特異的T細胞免疫のSCWへの成長、及び場合により自己抗原への成長に依存する。SCW導入モデルは、アジュバント誘導型又はコラーゲン誘導型の関節炎モデルよりも、薬剤試験に関しての使用頻度は低いが、各モデルはTNF阻害剤の抗炎症潜在力を正確に予測する。SCWモデルの慢性期は、マクロファージ依存性である。データの優位性は、RAでのマクロファージの重要な役割を示唆しているため、SCW関節炎モデルの慢性期を選択して、本発明の選択化合物が慢性関節炎及び骨侵食を低減する可能性を調査した。
Claims (30)
- 式Iの化合物であって、
ル、CO2Rd、CONReRf、C≡CRg又はCNであり、
式中、RdはH又は−C(1〜3)アルキルであり、
ReはH又は−C(1〜3)アルキルであり、
RfはH又は−C(1〜3)アルキルであり、及び
RgはH、−CH2OH又は−CH2CH2OHであり、
R2は3〜8個の炭素原子からなる飽和環又は部分的な不飽和環、スピロ置換シクロアルケニル、チオフェニル、ジヒドロスルホノピラニル、フェニル、フラニル、テトラヒドロピリジル又はジヒドロピラニルであり、そのいずれもが独立して、以下:塩素、フッ素、ヒドロキシ基、C(1〜3)アルキル及びC(1〜4)アルキル;それぞれ1つ又は2つによって置換されていてよく、
ZはH、F、Cl又はCH3であり、
JはCH又はNであり、
Xは
式中、RwはH、−C(1〜4)アルキル、−CO2C(1〜4)アルキル、−CONH2、−C
ONHC(1〜4)アルキル、−CON(C(1〜4)アルキル)2又は−COC(1〜4)アルキル
である、化合物、若しくはそれらの溶媒和物、水和物、互変異性体又は薬剤として許容される塩。 - 4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド塩酸塩;
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロ
ヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミドメタンスルホン酸塩;及び
4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド(1S)−(+)−10−カンファースルホン酸塩;からなる群から選択される、請求項9に記載の化合物。 - 4−シアノ−1H−イミダゾール−2−カルボン酸[2−(4,4−ジメチル−シクロヘキセ−1−エニル)−6−(2,2,6,6−テトラメチル−テトラヒドロ−ピラン−4−イル)−ピリジン−3−イル]−アミド塩酸塩である、請求項9に記載の化合物。
- 請求項1に記載の化合物及び製薬上許容できるキャリアを含む、医薬組成物。
- 請求項6に記載の化合物及び製薬上許容できるキャリアを含む、医薬組成物。
- 請求項8に記載の化合物及び製薬上許容できるキャリアを含む、医薬組成物。
- 請求項9に記載の化合物及び製薬上許容できるキャリアを含む、医薬組成物。
- 請求項9に記載の化合物を製薬上許容できるキャリアと混合することにより調製される、医薬組成物。
- 請求項9に記載の化合物を製薬上許容できるキャリアと混合することを含む、医薬組成物の製造方法。
- 骨粗鬆症、パジェット病、関節リウマチ及び他の形態の炎症性関節炎、変形性関節症、プロテーゼ破損、溶骨型腫瘍、骨髄腫並びに骨への腫瘍転移からなる群から選択される疾病を治療するための医薬組成物であって、請求項1に記載の化合物の少なくとも1種を治療上の有効量で含む、上記組成物。
- 糸球体腎炎、炎症性腸疾患、プロテーゼ破損、サルコイドーシス、欝血性閉塞性肺疾患、特発性肺胞線維症、ぜんそく、膵炎、ヒト免疫不全ウイルス感染症、乾癬、糖尿病、腫瘍関連血管新生、加齢関連黄斑変性症、糖尿病性網膜症、再狭窄、統合失調症及びアルツハイマー型認知症からなる群から選択される疾病を治療するための医薬組成物であって、請求項1に記載の化合物の少なくとも1種を治療上の有効量で含む、上記組成物。
- 哺乳類における、腫瘍転移若しくは変形性関節症によって引き起こされる骨格痛、又は内臓の痛み、炎症性の痛み若しくは神経原性疼痛を含む、痛みを治療するための医薬組成物であって、請求項1に記載の化合物の少なくとも1種を治療上の有効量で含む、上記組成物。
- 卵巣癌、子宮癌、乳癌、前立腺癌、肺癌、大腸癌、胃癌又は有毛細胞白血病からなる群から選択される疾病を治療するための医薬組成物であって、請求項1に記載の化合物の少なくとも1種を治療上の有効量で含む、上記組成物。
- 卵巣癌、子宮癌、乳癌、前立腺癌、肺癌、大腸癌、胃癌又は有毛細胞白血病からの転移を治療又は予防するための医薬組成物であって、請求項1に記載の化合物の少なくとも1種を治療上の有効量で含む、上記組成物。
- 全身性エリテマトーデス、関節リウマチ及び他の形態の炎症性関節炎、乾癬、シェーグレン症候群、多発性硬化症又はぶどう膜炎からなる群から選択される自己免疫疾患を治療するための医薬組成物であって、請求項1に記載の化合物の少なくとも1種を治療上の有効量で含む、上記組成物。
- 骨粗鬆症、パジェット病、関節リウマチ及び他の形態の炎症性関節炎、変形性関節症、プロテーゼ破損、溶骨型腫瘍、骨髄腫並びに骨への腫瘍転移からなる群から選択される疾病を治療するための医薬組成物であって、請求項9に記載の化合物の少なくとも1種を治療上の有効量で含む、上記組成物。
- 糸球体腎炎、炎症性腸疾患、プロテーゼ破損、サルコイドーシス、欝血性閉塞性肺疾患、特発性肺胞線維症、ぜんそく、膵炎、ヒト免疫不全ウイルス感染症、乾癬、糖尿病、腫瘍関連血管新生、加齢関連黄斑変性症、糖尿病性網膜症、再狭窄、統合失調症及びアルツハイマー型認知症からなる群から選択される疾病を治療するための医薬組成物であって、請求項9に記載の化合物の少なくとも1種を治療上の有効量で含む、上記組成物。
- 哺乳類における、腫瘍転移若しくは変形性関節症によって引き起こされる骨格痛、又は内臓の痛み、炎症性の痛み若しくは神経原性疼痛を含む痛みを治療するための医薬組成物であって、請求項9に記載の化合物の少なくとも1種を、治療上の有効量で含む、上記組成物。
- 卵巣癌、子宮癌、乳癌、前立腺癌、肺癌、大腸癌、胃癌又は有毛細胞白血病からなる群から選択される疾病を治療するための医薬組成物であって、請求項9に記載の化合物の少なくとも1種を治療上の有効量で含む、上記組成物。
- 卵巣癌、子宮癌、乳癌、前立腺癌、肺癌、大腸癌、胃癌又は有毛細胞白血病からの転移を治療又は予防するための医薬組成物であって、請求項9に記載の化合物の少なくとも1種を治療上の有効量で含む、上記組成物。
- 全身性エリテマトーデス、関節リウマチ及び他の形態の炎症性関節炎、乾癬、シェーグレン症候群、多発性硬化症又はぶどう膜炎からなる群から選択される自己免疫疾患を治療するための医薬組成物であって、請求項9に記載の化合物の少なくとも1種を治療上の有効量で含む、上記組成物。
- 骨粗鬆症、パジェット病、関節リウマチ及び他の形態の炎症性関節炎、変形性関節症、プロテーゼ破損、溶骨型腫瘍、骨髄腫並びに骨への腫瘍転移からなる群から選択される疾病を治療するための医薬組成物であって、請求項9に記載の化合物の少なくとも1種を治療上の有効量で含む、上記組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98062307P | 2007-10-17 | 2007-10-17 | |
US60/980,623 | 2007-10-17 | ||
PCT/US2008/080081 WO2009052237A1 (en) | 2007-10-17 | 2008-10-16 | Inhibitors of c-fms kinase |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011501752A JP2011501752A (ja) | 2011-01-13 |
JP5475672B2 true JP5475672B2 (ja) | 2014-04-16 |
Family
ID=40352814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010530095A Active JP5475672B2 (ja) | 2007-10-17 | 2008-10-16 | c−fmsキナーゼの阻害剤 |
Country Status (36)
Country | Link |
---|---|
US (1) | US8497376B2 (ja) |
EP (2) | EP3208269B1 (ja) |
JP (1) | JP5475672B2 (ja) |
KR (1) | KR101559326B1 (ja) |
CN (1) | CN101889009B (ja) |
AR (1) | AR068892A1 (ja) |
AU (1) | AU2008312540B2 (ja) |
BR (1) | BRPI0817843B8 (ja) |
CA (1) | CA2702898C (ja) |
CL (1) | CL2008003068A1 (ja) |
CO (1) | CO6270363A2 (ja) |
CR (1) | CR11433A (ja) |
CY (2) | CY1118717T1 (ja) |
DK (2) | DK3208269T3 (ja) |
EA (1) | EA018936B1 (ja) |
ES (2) | ES2614754T3 (ja) |
HR (2) | HRP20211593T1 (ja) |
HU (2) | HUE056173T2 (ja) |
IL (1) | IL205043A (ja) |
JO (1) | JO3240B1 (ja) |
LT (2) | LT3208269T (ja) |
MX (1) | MX2010004263A (ja) |
MY (1) | MY153951A (ja) |
NI (1) | NI201000059A (ja) |
NZ (1) | NZ584574A (ja) |
PA (1) | PA8799701A1 (ja) |
PE (1) | PE20090972A1 (ja) |
PL (2) | PL2215079T3 (ja) |
PT (2) | PT2215079T (ja) |
RS (2) | RS62569B1 (ja) |
SI (2) | SI3208269T1 (ja) |
TW (1) | TWI440637B (ja) |
UA (1) | UA99311C2 (ja) |
UY (1) | UY31397A1 (ja) |
WO (1) | WO2009052237A1 (ja) |
ZA (1) | ZA201003429B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020510673A (ja) * | 2017-03-03 | 2020-04-09 | ヤンセン バイオテツク,インコーポレーテツド | がんの治療のための低分子csf−1r阻害剤とcd40に特異的に結合するアゴニスト抗体とを含む併用療法 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
JP5331681B2 (ja) | 2006-04-20 | 2013-10-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | c−fmsキナーゼの阻害剤 |
MX2008013533A (es) | 2006-04-20 | 2009-01-15 | Janssen Pharmaceutica Nv | Compuestos heterociclicos como inhibidores de c-fms cinasa. |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
US20120271046A1 (en) | 2011-04-19 | 2012-10-25 | Jeffrey Christopher S | Nitrogen-containing heterocyclic compounds and methods of making the same |
JOP20180012A1 (ar) * | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
EP2882757B1 (en) * | 2012-08-07 | 2016-10-05 | Janssen Pharmaceutica, N.V. | Process for the preparation of heterocyclic ester derivatives |
JP6262732B2 (ja) | 2012-08-16 | 2018-01-17 | ヤンセン ファーマシューティカ エヌ.ベー. | N型カルシウムチャネル遮断剤としての置換ピラゾール |
ES2662600T3 (es) * | 2013-03-15 | 2018-04-09 | Janssen Pharmaceutica, N.V. | Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa |
MX2015012344A (es) | 2013-03-15 | 2016-06-02 | Janssen Pharmaceutica Nv | 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrameti ltetrahidro-2h-piran-4-il)piridin-3-il)-1h-imidazol-2-carboxamida para el tratamiento de linfona de hodgkin. |
US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
SG11201600846WA (en) * | 2013-08-16 | 2016-03-30 | Janssen Pharmaceutica Nv | Substituted imidazoles as n-type calcium channel blockers |
GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
KR102100539B1 (ko) * | 2013-12-19 | 2020-04-13 | 아처 다니엘 미드랜드 캄파니 | 푸란-2,5-디메탄올 및 (테트라하이드로푸란-2,5-디일)디메탄올의 모노- 및 디알킬 에테르 및 그 양친매성 유도체 |
JP6537338B2 (ja) * | 2015-04-24 | 2019-07-03 | 日東電工株式会社 | 核酸固相合成用リンカー及び担体 |
KR20180107142A (ko) * | 2016-02-11 | 2018-10-01 | 바이엘 크롭사이언스 악티엔게젤샤프트 | 해충 방제제로서의 치환된 2-옥시이미다졸릴-카르복스아미드 |
TWI752980B (zh) * | 2016-07-18 | 2022-01-21 | 比利時商健生藥品公司 | 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之晶型 |
TW201811326A (zh) * | 2016-07-18 | 2018-04-01 | 比利時商健生藥品公司 | 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之鹽形式 |
JOP20190282A1 (ar) | 2017-06-09 | 2019-12-05 | Novartis Ag | مركبات وتركيبات لحث تكوّن الغضاريف |
CN109467538A (zh) * | 2017-09-07 | 2019-03-15 | 和记黄埔医药(上海)有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
BR112021011894A2 (pt) | 2018-12-21 | 2021-09-08 | Daiichi Sankyo Company, Limited | Composição farmacêutica |
WO2020222109A1 (en) | 2019-05-02 | 2020-11-05 | Janssen Biotech, Inc. | Csf-1/csf-1r gene set |
CN110575450B (zh) * | 2019-09-17 | 2023-03-31 | 遵义医科大学珠海校区 | 2,5-呋喃二甲醇在制备抗肿瘤药物中的应用 |
WO2021144360A1 (en) | 2020-01-17 | 2021-07-22 | F. Hoffmann-La Roche Ag | Small molecule csf-1r inhibitors in therapeutic and cosmetic uses |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2466420A (en) | 1947-11-26 | 1949-04-05 | Eastman Kodak Co | Ketene condensation products with aldehydes |
US3226394A (en) * | 1964-06-16 | 1965-12-28 | Shulton Inc | Pyridylethylated anthranilamides and derivatives thereof |
CH504416A (de) | 1966-12-05 | 1971-03-15 | Ciba Geigy Ag | Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen |
US4551540A (en) | 1983-01-17 | 1985-11-05 | Borg-Warner Chemicals, Inc. | Substituted 2,5-dimethylpyrroles |
US5190541A (en) * | 1990-10-17 | 1993-03-02 | Boston Scientific Corporation | Surgical instrument and method |
EP0627940B1 (en) * | 1992-03-05 | 2003-05-07 | Board of Regents, The University of Texas System | Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors |
US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
US5686472A (en) | 1992-10-29 | 1997-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5593992A (en) | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
WO1996011932A1 (en) | 1994-10-14 | 1996-04-25 | Smithkline Beecham Plc | 2-(imidazol-4-yl)carbapeneme derivatives, intermediates thereof and use as antibacterials |
JPH10506560A (ja) | 1995-04-19 | 1998-06-30 | シュナイダー(ユーエスエー)インク | 薬品を放出する被覆されたステント |
US6117432A (en) * | 1995-04-20 | 2000-09-12 | Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) | Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence |
TW349948B (en) * | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
CA2231105C (en) | 1995-12-08 | 2005-09-13 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives |
US5874442A (en) * | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
US5702390A (en) * | 1996-03-12 | 1997-12-30 | Ethicon Endo-Surgery, Inc. | Bioplar cutting and coagulation instrument |
CA2262676A1 (en) | 1996-08-09 | 1998-02-19 | Merck & Co., Inc. | Stereoselective deoxygenation reaction |
UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
JP2001505548A (ja) | 1996-12-20 | 2001-04-24 | トヴァリシェストヴォ エス オグラニチェンノイ オトヴェトストヴェンノストジュ“タブジュファーム” | 凍結乾燥ハイドロクロライド−1β,10β−エポキシ−13−ジメチルアミノ−グアヤ−3(4)−エン−6,12−オリドの生成方法および装置 |
TW591030B (en) | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
AU738628B2 (en) | 1997-04-25 | 2001-09-20 | Janssen Pharmaceutica N.V. | Farnesyltransferase inhibiting quinazolinones |
TW491872B (en) | 1997-05-27 | 2002-06-21 | Ciba Sc Holding Ag | Block oligomers containing l-hydrocarbyloxy-2,2,6,6-tetramethyl-4- piperidyl groups as stabilizers for lower polyolefin |
US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
DE69902012T2 (de) | 1998-03-05 | 2002-11-21 | Formula One Administration Ltd | Datenübertragungssystem |
US6303654B1 (en) | 1998-03-12 | 2001-10-16 | Wisconsin Alumni Research Foundation | Acyclic monoterpenoid derivatives |
WO2000001691A1 (en) | 1998-07-01 | 2000-01-13 | Merck & Co., Inc. | Process for making farnesyl-protein transferase inhibitors |
WO2000002871A1 (en) | 1998-07-10 | 2000-01-20 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
WO2000012498A1 (en) | 1998-08-27 | 2000-03-09 | Pfizer Products Inc. | Quinolin-2-one derivatives useful as anticancer agents |
JP3495706B2 (ja) | 1998-08-27 | 2004-02-09 | ファイザー・プロダクツ・インク | 抗癌薬として有用なアルキニル置換キノリン−2−オン誘導体 |
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
ATE240327T1 (de) * | 1998-12-23 | 2003-05-15 | Janssen Pharmaceutica Nv | 1,2-annelierte chinolinderivate |
JP4876239B2 (ja) * | 1999-01-11 | 2012-02-15 | プリンストン ユニバーシティー | 標的確認のための高親和性阻害剤およびその使用 |
RU2312860C2 (ru) * | 1999-04-15 | 2007-12-20 | Бристол-Маерс Сквибб Компани | Циклические ингибиторы протеинтирозинкиназ |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
WO2000064946A2 (en) * | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
US6346625B1 (en) | 1999-06-23 | 2002-02-12 | Astrazeneca Ab | Protein kinase inhibitors |
DE19962924A1 (de) * | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
EP1246823A1 (en) | 1999-12-28 | 2002-10-09 | Pharmacopeia, Inc. | Pyrimidine and triazine kinase inhibitors |
FR2803592A1 (fr) | 2000-01-06 | 2001-07-13 | Aventis Cropscience Sa | Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant. |
US6558385B1 (en) * | 2000-09-22 | 2003-05-06 | Tissuelink Medical, Inc. | Fluid-assisted medical device |
US6692491B1 (en) * | 2000-03-24 | 2004-02-17 | Scimed Life Systems, Inc. | Surgical methods and apparatus for positioning a diagnostic or therapeutic element around one or more pulmonary veins or other body structures |
US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US6960590B2 (en) | 2000-10-17 | 2005-11-01 | Merck & Co. Inc. | Orally active salts with tyrosine kinase activity |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
WO2003024969A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
IL161156A0 (en) | 2001-10-30 | 2004-08-31 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
AU2002360753B2 (en) | 2001-12-27 | 2008-08-21 | Theravance, Inc. | Indolinone derivatives useful as protein kinase inhibitors |
CA2486183C (en) | 2002-05-23 | 2012-01-10 | Cytopia Pty Ltd. | Protein kinase inhibitors |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
JP4741948B2 (ja) | 2002-08-14 | 2011-08-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターおよびそれらの使用 |
WO2004018419A2 (en) | 2002-08-23 | 2004-03-04 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
WO2004022525A1 (en) | 2002-09-05 | 2004-03-18 | Neurosearch A/S | Amide derivatives and their use as chloride channel blockers |
JP4560483B2 (ja) * | 2002-10-03 | 2010-10-13 | ターゲジェン インコーポレーティッド | 血管静態化物質およびそれらの使用法 |
JPWO2004039782A1 (ja) | 2002-10-29 | 2006-03-02 | 麒麟麦酒株式会社 | Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
CA2501932C (en) | 2002-11-13 | 2014-03-11 | Chiron Corporation | Use of benzimidazole quinolinones for treating cancer |
AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
AU2003297160A1 (en) | 2002-12-18 | 2004-07-22 | Vertex Pharmaceuticals Incorporated | Benzisoxazole derivatives useful as inhibitors of protein kinases |
KR20050119201A (ko) * | 2003-04-09 | 2005-12-20 | 니뽄 다바코 산교 가부시키가이샤 | 5원 헤테로방향족 고리 화합물 및 이의 의약적 용도 |
US7790724B2 (en) * | 2003-04-25 | 2010-09-07 | Janssen Pharmaceutica N.V. | c-fms kinase inhibitors |
US7429603B2 (en) * | 2003-04-25 | 2008-09-30 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
US20050113566A1 (en) * | 2003-04-25 | 2005-05-26 | Player Mark R. | Inhibitors of C-FMS kinase |
US7427683B2 (en) * | 2003-04-25 | 2008-09-23 | Ortho-Mcneil Pharmaceutical, Inc. | c-fms kinase inhibitors |
CN1856461A (zh) | 2003-07-28 | 2006-11-01 | 史密丝克莱恩比彻姆公司 | 作为雌激素受体调节剂的亚环烷基化合物 |
JP4971797B2 (ja) | 2003-10-23 | 2012-07-11 | アブ サイエンス | チロシンキナーゼ阻害薬としての2−アミノアリールオキサゾール化合物 |
GB0326601D0 (en) | 2003-11-14 | 2003-12-17 | Novartis Ag | Organic compounds |
NZ548884A (en) | 2004-01-30 | 2010-06-25 | Ab Science | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors |
EP1807077B1 (en) * | 2004-10-22 | 2016-11-23 | Janssen Pharmaceutica NV | Inhibitors of c-fms kinase |
US7662837B2 (en) * | 2004-10-22 | 2010-02-16 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
AU2005299501B2 (en) * | 2004-10-22 | 2011-03-03 | Janssen Pharmaceutica N.V. | Aromatic amides as inhibitors of c-fms kinase |
US7645755B2 (en) * | 2004-10-22 | 2010-01-12 | Janssen Pharmaceutical N.V. | Inhibitors of c-fms kinase |
DE102005023588A1 (de) | 2005-05-18 | 2006-11-23 | Grünenthal GmbH | Salze substituierter Allophansäureester und deren Verwendung in Arzneimitteln |
US20060281755A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
US20060281771A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
US20060281700A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
US20060281769A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
CA2626623C (en) | 2005-10-18 | 2016-08-30 | Janssen Pharmaceutica N.V. | Method of inhibiting flt3 kinase |
NZ572201A (en) * | 2006-04-20 | 2011-09-30 | Janssen Pharmaceutica Nv | Inhibitors of c-fms kinase |
MX2008013533A (es) * | 2006-04-20 | 2009-01-15 | Janssen Pharmaceutica Nv | Compuestos heterociclicos como inhibidores de c-fms cinasa. |
JP5331681B2 (ja) * | 2006-04-20 | 2013-10-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | c−fmsキナーゼの阻害剤 |
US8697716B2 (en) * | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
-
2008
- 2008-10-15 JO JOP/2008/0464A patent/JO3240B1/ar active
- 2008-10-16 UA UAA201005857A patent/UA99311C2/ru unknown
- 2008-10-16 DK DK16203884.8T patent/DK3208269T3/da active
- 2008-10-16 CA CA2702898A patent/CA2702898C/en active Active
- 2008-10-16 LT LTEP16203884.8T patent/LT3208269T/lt unknown
- 2008-10-16 DK DK08839490.3T patent/DK2215079T3/en active
- 2008-10-16 PL PL08839490T patent/PL2215079T3/pl unknown
- 2008-10-16 CL CL2008003068A patent/CL2008003068A1/es unknown
- 2008-10-16 MY MYPI2010001696A patent/MY153951A/en unknown
- 2008-10-16 RS RS20211326A patent/RS62569B1/sr unknown
- 2008-10-16 NZ NZ584574A patent/NZ584574A/en unknown
- 2008-10-16 PT PT88394903T patent/PT2215079T/pt unknown
- 2008-10-16 MX MX2010004263A patent/MX2010004263A/es active IP Right Grant
- 2008-10-16 BR BRPI0817843A patent/BRPI0817843B8/pt active IP Right Grant
- 2008-10-16 LT LTEP08839490.3T patent/LT2215079T/lt unknown
- 2008-10-16 HR HRP20211593TT patent/HRP20211593T1/hr unknown
- 2008-10-16 PT PT162038848T patent/PT3208269T/pt unknown
- 2008-10-16 TW TW097139644A patent/TWI440637B/zh active
- 2008-10-16 JP JP2010530095A patent/JP5475672B2/ja active Active
- 2008-10-16 RS RS20170252A patent/RS55860B1/sr unknown
- 2008-10-16 ES ES08839490.3T patent/ES2614754T3/es active Active
- 2008-10-16 EP EP16203884.8A patent/EP3208269B1/en active Active
- 2008-10-16 EP EP08839490.3A patent/EP2215079B1/en active Active
- 2008-10-16 WO PCT/US2008/080081 patent/WO2009052237A1/en active Application Filing
- 2008-10-16 ES ES16203884T patent/ES2905118T3/es active Active
- 2008-10-16 US US12/252,439 patent/US8497376B2/en active Active
- 2008-10-16 HU HUE16203884A patent/HUE056173T2/hu unknown
- 2008-10-16 AR ARP080104507A patent/AR068892A1/es active IP Right Grant
- 2008-10-16 SI SI200832183T patent/SI3208269T1/sl unknown
- 2008-10-16 UY UY31397A patent/UY31397A1/es unknown
- 2008-10-16 AU AU2008312540A patent/AU2008312540B2/en active Active
- 2008-10-16 HU HUE08839490A patent/HUE031555T2/en unknown
- 2008-10-16 EA EA201070480A patent/EA018936B1/ru unknown
- 2008-10-16 KR KR1020107010750A patent/KR101559326B1/ko active IP Right Grant
- 2008-10-16 CN CN200880119756.0A patent/CN101889009B/zh active Active
- 2008-10-16 PL PL16203884T patent/PL3208269T3/pl unknown
- 2008-10-16 SI SI200831776A patent/SI2215079T1/sl unknown
- 2008-10-17 PA PA20088799701A patent/PA8799701A1/es unknown
- 2008-10-17 PE PE2008001797A patent/PE20090972A1/es active IP Right Grant
-
2010
- 2010-04-13 IL IL205043A patent/IL205043A/en active IP Right Grant
- 2010-04-15 NI NI201000059A patent/NI201000059A/es unknown
- 2010-04-30 CO CO10051581A patent/CO6270363A2/es not_active Application Discontinuation
- 2010-05-14 ZA ZA2010/03429A patent/ZA201003429B/en unknown
- 2010-05-17 CR CR11433A patent/CR11433A/es not_active Application Discontinuation
-
2017
- 2017-03-09 HR HRP20170393TT patent/HRP20170393T1/hr unknown
- 2017-03-14 CY CY20171100322T patent/CY1118717T1/el unknown
-
2021
- 2021-11-08 CY CY20211100960T patent/CY1124721T1/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020510673A (ja) * | 2017-03-03 | 2020-04-09 | ヤンセン バイオテツク,インコーポレーテツド | がんの治療のための低分子csf−1r阻害剤とcd40に特異的に結合するアゴニスト抗体とを含む併用療法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5475672B2 (ja) | c−fmsキナーゼの阻害剤 | |
US9790212B2 (en) | Enhancer of zeste homolog 2 inhibitors | |
JP6110859B2 (ja) | ヤヌスキナーゼ阻害剤としてのピラゾールカルボキサミド | |
JP2022515879A (ja) | 複素環式化合物、中間体、その製造方法及び応用 本願は、出願日が2018年12月29日の中国特許出願cn 201811642319、出願日が2019年05月24日の中国特許出願cn201910440214.3及び出願日が2019年10月24日の中国特許出願cn201911016158.7に基づいて優先権を主張する。また、上記中国特許出願の全文は本願に援用される。 | |
US20150111865A1 (en) | Trk-INHIBITING COMPOUND | |
JP6305510B2 (ja) | ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾロピリドン | |
KR20090003343A (ko) | C-fms 키나제의 저해제 | |
JP2015526411A (ja) | 窒素複素環誘導体及びその医薬品への応用 | |
US20230159522A1 (en) | Bcl-2 inhibitor | |
CN116745283A (zh) | 用于治疗trpm3介导的病症的杂环衍生物 | |
AU2022285899A1 (en) | 3-pyrrolylsulfonamide compounds as gpr17 antagonists | |
AU2013203813B2 (en) | Inhibitors of C-FMS kinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111011 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130808 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130820 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131212 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140121 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140206 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5475672 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |